Introduction {#s1}
============

Wnt morphogens, secreted cysteine-rich palmitoleoylated glycoproteins, play critical roles in cell-fate determination, tissue homeostasis and embryonic development ([@bib24]; [@bib48]). Aberrant Wnt signalling leads to cancer, osteoporosis and degenerative illnesses ([@bib5]). Norrie Disease Protein (*NDP*) gene encodes Norrin ([@bib13]; [@bib21]), a secreted cystine-knot like growth factor, distinct from the lipid-modified Wnt ([@bib87]). Norrin activates the canonical Wnt/β-catenin pathway by interaction with Wnt receptor Frizzled4 cysteine-rich domain (Fz4~CRD~), and co-receptor low density lipoprotein receptor related protein 5/6 ectodomain (Lrp5/6~ECD~), plus the auxiliary four-pass transmembrane protein Tetraspanin-12 (Tspan-12) and glycosaminoglycans (GAGs) of heparan sulfate proteoglycans (HSPGs) ([@bib89]; [@bib37]; [@bib42]).

The Norrin mediated pathway maintains the blood-retina and blood-brain barriers ([@bib86]) and regulates angiogenesis in the cochlea and uterus ([@bib67]; [@bib90]) as well as neuroprotective effects on retinal neurons ([@bib57]; [@bib74]). Mutations in the *NDP* gene and the receptor genes, *FZ4*, *LRP5*, and *TSPAN-12*, have been identified for vitreoretinal diseases including Norrie Disease, Familial Exudative Vitreoretinopathy, and Coats\' Disease ([@bib55]; [@bib91]; [@bib58]). *NDP*, *FZ4*, *LRP5*, and *TSPAN-12* knock-out mice experiments further support the notion that dysfunctional Norrin signalling results in impaired retinal angiogenesis ([@bib69]; [@bib40]; [@bib71]; [@bib89]; [@bib37]). Unlike Wnts which have promiscuous interactions with Fz receptors, Norrin specifically binds to Fz4~CRD~, but not to the 14 other CRDs of Fz and secreted Frizzled-related protein (sFRP) family members ([@bib34]; [@bib77]). Similar to Wnt, Norrin (1) binds to Lrp5/6~ECD~ ([@bib42]); (2) interacts with HSPGs and shows limited spatial diffusion ([@bib60]; [@bib89]; [@bib77]; [@bib57]). As well as being a potential target for therapeutic interventions, an understanding of Norrin mediated signalling will also provide insights into the fundamental features required to trigger canonical Wnt/β-catenin signalling.

Structural analyses of the extracellular components and interactions mediating Norrin signalling were considered to be challenging because of the difficulties of generating recombinant Norrin ([@bib60]; [@bib75]; [@bib57]). [@bib42] reported a refolding method (from *Escherichia coli* inclusion bodies) to produce active recombinant Norrin fused with a N-terminal maltose binding protein (MBP-Norrin), an advance that enabled them to determine the crystal structure of MBP-Norrin. Here, we develop an efficient mammalian cell expression method to produce active untagged recombinant Norrin and detail the structural and functional properties of this potential therapeutic agent. Our crystallographic and solution studies further reveal that dimeric Norrin forms a complex with two copies of monomeric Fz4~CRD~. Our molecular level analysis of the Norrin--Fz4~CRD~ complex bound with GAG analogue, in combination with structure-guided biophysical and cell-based studies, defines the basis for ligand recognition. Structural comparison with the *Xenopus* Wnt8 in complex with mouse Fz8~CRD~ ([@bib35]) shows that Norrin uses its β-strands to mimic a finger-like loop in Wnt for binding to the Fz receptor CRD. Finally, we note that engineered Norrin mutants resulting from our analyses may be of use as agents for blocking Wnt receptor activation.

Results {#s2}
=======

Production of biologically active Norrin {#s2-1}
----------------------------------------

To address the challenge of producing Norrin in large quantities, we screened conditions and constructs for Norrin expression ([Figure 1A](#fig1){ref-type="fig"}). We found that fusion of Norrin to the C-terminus of small ubiquitin-like modifier (SUMO) ([@bib62]), in combination with addition of valproic acid ([@bib8]), a putative histone deacetylase inhibitor, substantially boosted expression of the secreted protein in human embryonic kidney (HEK) 293T cells ([Figure 1B,C](#fig1){ref-type="fig"}). After removal of the SUMO fusion tag, the recombinant Norrin shows a monodispersed state in size-exclusion chromatography (SEC; [Figure 1D](#fig1){ref-type="fig"}) and is biologically active in a cell-based luciferase reporter assay ([Figure 1E](#fig1){ref-type="fig"}).10.7554/eLife.06554.003Figure 1.Expression and purification of biologically active recombinant Norrin.(**A**) Schematic diagrams of the expression constructs including Norrin (a signal peptide, SP, followed by Norrin and Rho-1D4 tag at C-terminus) and SUMO-Norrin (a SP followed by a Strep-tag II, an octahistidine, SUMO, HRV 3C protease cleavage site, Norrin, and Rho-1D4 tag at C-terminus). (**B** and **C**) Conditioned media from transfected HEK293T cells were immunoblotted (IB) with the anti-Rho-1D4 antibody. (**B**) SUMO fusion improves Norrin secreted expression. (**C**) The expression level of SUMO tagged Norrin was further boosted for HEK-293T cells treated with valproic acid. (**D**) SEC elution profile and SDS-PAGE under reducing conditions with fractions analysed marked by red lines. (**E**) Purified recombinant untagged Norrin actives the canonical Wnt/β-catenin pathway in the luciferase reporter assay. RLU: relative light unit. Error bars indicate standard deviations (n = 3).**DOI:** [http://dx.doi.org/10.7554/eLife.06554.003](10.7554/eLife.06554.003)

The crystal structure of Norrin and its oligomeric state in solution {#s2-2}
--------------------------------------------------------------------

We determined three crystal structures of Norrin ([Figure 2A](#fig2){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"}), using selenomethionine-labeled protein for phasing ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). The Norrin protein fold is identical to that of the previously reported MBP-Norrin crystal structure ([@bib42]). Each Norrin monomer comprises three β-hairpins (β1-β2, β3-β4 and β5-β6), a β7 strand at the C-terminus, and four intramolecular disulphide bonds ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). The two monomers assemble as an elongated, head-to-tail, dimer ([Figure 2A](#fig2){ref-type="fig"}) stabilized by three intermolecular disulphide bridges (Cys93-Cys95, Cys95-Cys93, and Cys131-Cys131), in agreement with small-angle X-ray scattering (SAXS) measurements which showed Norrin dimer in solution ([Figure 2---figure supplement 3A](#fig2s3){ref-type="fig"} and [Table 2](#tbl2){ref-type="table"}). The dimer interface is further stabilized by extensive hydrogen bonds and hydrophobic interactions ([Figure 2---figure supplement 3B,C](#fig2s3){ref-type="fig"}). Superposition of all molecules in the asymmetric units from our three crystal forms with the MBP-Norrin structure ([@bib42]) showed an average root-mean-square (r.m.s.) deviation of 1.5 Å over 190 equivalent Cα atoms ([Figure 2---figure supplement 3D](#fig2s3){ref-type="fig"}). On inspection the superpositions revealed a high degree of conformational plasticity in the β1-β2, β3-β4 and β5-β6 loops ([Figure 2B](#fig2){ref-type="fig"}). The flexibility inherent in these regions is consistent with the relatively high crystallographic B factor values ([Figure 2C](#fig2){ref-type="fig"}). Conversely, the structural comparisons underscore the conserved nature of the interface at the dimer core. It has previously been noted that disruption of the dimer by either Cysteine-to-Alanine mutations of intermolecular disulphide bonds or mutations of hydrophobic residues at the dimer interface results in a loss of Norrin-mediated signalling ([@bib77]; [@bib42]).10.7554/eLife.06554.004Figure 2.Crystal structure and structural analysis of apo Norrin.(**A**) Schematic diagram of Norrin is rainbow coloured and disulphide bonds are drawn as lines. Cartoon representation of dimeric Norrin. Four intramolecular disulphide bonds are shown as magenta sticks. Cys93, Cys95, and Cys131 (forming intermolecular disulphide bridges) are shown as cyan, blue, and green sticks, respectively. Two cystine-knot motifs are marked with dotted boxes and the filled circles denote the N- and C-termini. (**B**) Ribbon diagram of superpositions of Norrin molecules from the asymmetric unit of crystal form I (green, chain A and B; cyan, chain C and D; magenta, chain E and F), crystal form II (yellow, chain A and B; blue, chain C and D), crystal form III (grey, chain A and B; purple, chain C and D), and MBP-Norrin (cyan; PDB ID: 4MY2). The flexible regions are highlighted as red lines. Loop regions (β1-β2 loop, β3-β4 loop, and β5-β6 loop) show structural plasticity. The well ordered regions include the cystine-knot motifs plus intermolecular disulphide linked areas (black circle) and two Fz4 binding sites (cyan dotted circle). (**C**) Representative Norrin dimer displayed with the diameter of the Cα tube defined by Cα atom B factor (small tube means structural rigidity; large tube indicates structural flexibility).**DOI:** [http://dx.doi.org/10.7554/eLife.06554.004](10.7554/eLife.06554.004)10.7554/eLife.06554.005Figure 2---figure supplement 1.Electron density map of Norrin structure.The initial density modified map from PHENIX AUTOSOL (Terwilliger, 2000, Terwilliger et al., 2009) calculated with experimental Se-Met SAD phases is contoured at 1.5 σ and shown as blue meshes. The initial model from BUCCANEER ([@bib25]) is shown as magenta ribbon diagram. The anomalous difference map for Se-Met is contoured at 4 σ as green meshes with Se-Met residues labelled.**DOI:** [http://dx.doi.org/10.7554/eLife.06554.005](10.7554/eLife.06554.005)10.7554/eLife.06554.006Figure 2---figure supplement 2.Multiple sequence alignment of Norrin.Secondary structure element colouring corresponds to [Figure 2A](#fig2){ref-type="fig"}. The magenta boxes represent conserved cysteine residues in the cystine-knot growth factor superfamily, whereas the yellow boxes denote Norrin specific conserved cysteine residues. Disulphide bridges are numbered and are drawn in magenta lines for the intramolecular disulphide bonds. Three cysteine residues (highlighted in cyan) that form intermolecular disulphide bridges are drawn in cyan, blue and green lines. Triangles indicate the mutation sites for SPR binding and luciferase reporter assays. Residues involved in binding of Fz4, GAG, and Lrp5/6 are marked with blue, green, and yellow filled boxes, respectively. Residues involved in dimerization are highlighted with orange filled boxes. Black boxes denote the region of the Wnt8 index finger involved in Fz8~CRD~ binding, which overlaps with Norrin for Fz4~CRD~ binding ([Figure 9](#fig9){ref-type="fig"}). Disease-associated residues are marked by coloured dots according to the types of mutations (purple, missense; cyan, frame-shift; black, nonsense). Cysteine residues associated with diseases are marked below the sequence with red filled boxes. NCBI accession numbers: Human Norrin, NP_000257; Monkey Norrin, XP_528948; Panda Norrin, XP_002928194; Pig Norrin, NP_001106528; Dog Norrin, XP_855261; Bovine Norrin, AAI12739; Horse Norrin, XP_001490401; Rabbit Norrin, XP_002719919; Mouse Norrin, NP_035013; Chicken Norrin, XP_416765; Frog Norrin, NP_001154869; Fish Norrin, XP_001338820.**DOI:** [http://dx.doi.org/10.7554/eLife.06554.006](10.7554/eLife.06554.006)10.7554/eLife.06554.007Figure 2---figure supplement 3.Norrin solution structure and structural analyses.(**A**) SAXS analysis of Norrin. The experimental scattering data (black circles) and calculated scattering pattern (green line) are shown and the Norrin solution structure model is shown in cartoon representation. The upper right inset shows the experimental (black circles) and calculated (green line) Guinier region. The dashed lines delimit the range of fitting for Radius of gyration (*R*~g~) analysis (*R*~g~·*S* ≤ 1.3). The bottom right inset shows the experimental (black line) and calculated (green line) pair distance distribution *P*(r) curve. (**B**) Hydrophobic interactions for Norrin dimerization beyond the cystine-knot motif. Resides on hairpin A and C (yellow sticks) form hydrophobic contacts with the residues on hairpin B (cyan sticks) from another monomer. Residues associated with diseases are boxed. (**C**) Table of hydrogen bond and salt-bridge interactions in the Norrin dimer interface. Missense and nonsense mutations are highlighted as filled grey and purple backgrounds, respectively. (**D**) Detailed information of structural comparison shown as root mean square (r.m.s) deviation (Å) values and the number of aligned Cα atoms (in brackets).**DOI:** [http://dx.doi.org/10.7554/eLife.06554.007](10.7554/eLife.06554.007)10.7554/eLife.06554.008Table 1.Data collection, phasing and refinement statistics**DOI:** [http://dx.doi.org/10.7554/eLife.06554.008](10.7554/eLife.06554.008)Norrin--Fz4~CRD~--SOSMethylated Norrin--Fz4~CRD~NorrinNorrin Se-MetMethylated NorrinCrystal formIIIIData collectionSpace group*P*6~1~22*P*4~3~22*P*2~1~2~1~2~1~*P*2~1~2~1~2~1~*P*2~1~2~1~2~1~Cell dimensions *a*, *b*, *c* (Å)119.1, 119.1, 119.298.9, 98.9, 120.446.4, 79.1, 243.345.8, 78.8, 232.8102.7, 53.1, 96.1 *α*, *β*, *γ* (°)90, 90, 9090, 90, 12090, 90, 9090, 90, 9090, 90, 90*Peak*Wavelength0.92000.97950.96860.97950.9795Resolution (Å)47.34--3.00 (3.18-- 3.00)49.46--2.30 (2.38--2.30)65.56--2.40 (2.49--2.40)116.39--3.18 (3.26--3.18)33.65--2.00 (2.05--2.00)*R*~pim~ (%)3.1 (54.8)4.5 (56.1)6.1 (42.3)2.8 (23.4)4.1 (58.3)*I*/σ*I*14.6 (1.6)10.7 (1.4)7.8 (1.9)20.2 (3.0)9.1 (1.7)Completeness (%)100 (100)98.9 (97.2)99.9 (100)99.9 (99.9)100 (100)Redundancy19.6 (20.6)6.0 (5.6)5.6 (5.7)33.3 (9.9)5.6 (5.8)RefinementResolution (Å)47.34--3.00 (3.18--3.00)49.46--2.30 (2.38--2.30)65.56--2.40 (2.49--2.40)33.65--2.00 (2.05--2.00)No. reflections10,503 (1648)26,816 (2514)34,722 (3384)36,272 (2635)*R*~work~/*R*~free~21.5/26.719.7/22.121.6/26.223.3/24.8No. atoms Protein1759255749303187 Ligand/ion833910110 Water0115164122*B*-factors Protein113637057 Ligand/ion133719273 Water0575551R.m.s deviations Bond lengths (Å)0.0050.0040.0090.005 Bond angles (°)1.180.931.081.07Ramachandran plot Favored (%)95.597.096.797.2 Allowed (%)4.53.03.32.8PDB code5BQC5BQE5BPU5BQ8NorrinFz4~CRD~Fz4~CRD~Crystal formIIIIIIData collectionSpace group*C*121*P*2~1~2~1~2~1~*P*6~1~Cell dimensions *a*, *b*, *c* (Å)86.8, 38.1, 177.272.6, 102.1, 116.576.1, 76.1, 204.5 *α*, *β*, *γ* (°)90, 94, 9090, 90, 9090, 90, 90Wavelength0.97950.96860.9686Resolution (Å)44.19--2.30 (2.38--2.30)41.77--2.20 (2.27--2.20)47.37--2.40 (2.49--2.40)*R*~pim~ (%)2.8 (36)4.1 (49.5)2.6 (33.9)*I*/σ*I*16.7 (2.0)12.8 (2.0)14.5 (2.2)Completeness (%)99.2 (97.7)99.2 (99.7)99.5 (99.4)Redundancy5.8 (6.0)4.3 (4.4)4.0 (4.1)RefinementResolution (Å)44.19--2.30 (2.38--2.30)41.77--2.20 (2.27--2.20)47.37--2.40 (2.49--2.40)No. reflections26,073 (2538)44,268 (3802)25,975 (2724)*R*~work~/*R*~free~22.1/25.017.7/22.320.3/24.3No. atoms Protein310438663877 Ligand/ion727099 Water5414869*B*-factors Protein914776 Ligand/ion726772 Water1424368R.m.s deviations Bond lengths (Å)0.0060.010.005 Bond angles (°)1.031.350.94Ramachandran plot Favored (%)96.099.097.0 Allowed (%)4.01.03.0PDB code5BQB5BPB5BPQ[^3][^4]10.7554/eLife.06554.009Table 2.Molecular properties of the proteins determined by SAXS**DOI:** [http://dx.doi.org/10.7554/eLife.06554.009](10.7554/eLife.06554.009)ProteinsN-Glyc state*R*~g~ (nm)[\*](#tblfn1){ref-type="table-fn"}*D*~max~ (nm)[†](#tblfn2){ref-type="table-fn"}Volume porod (*V*~p~ \[nm^3^\])MW~Theoretical~ (kDa)[‡](#tblfn3){ref-type="table-fn"}MW~Measured~ (KDa)[§](#tblfn4){ref-type="table-fn"}MW~Measured~ (KDa)[\#](#tblfn5){ref-type="table-fn"}Fz4~CRD~deglyc[¶](#tblfn6){ref-type="table-fn"}1.986.9333.017.1 (monomer)15.919.9Fz4~CRD~glyc[\*\*](#tblfn7){ref-type="table-fn"}2.247.8441.121.4 (monomer)23.724.7Norrin2.749.1837.427.2 (dimer)33.522.5Norrin--Fz4~CRD~deglyc[¶](#tblfn6){ref-type="table-fn"}3.4111.9293.861.3 (2:2 complex)57.956.5[^5][^6][^7][^8][^9][^10][^11]

The crystal structure of Fz4~CRD~ {#s2-3}
---------------------------------

We determined two crystal structures of Fz4~CRD~ ([Figure 3](#fig3){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"}). Similar to mouse Fz8~CRD~ ([@bib27]) the Fz4~CRD~ fold comprises four α helices ([Figure 3A](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}) stabilized by five disulphide bridges (Cys45--Cys106, Cys53--Cys99, Cys90--Cys128, Cys117--Cys158, Cys121--Cys145). The N-acetylglucosamines on two N-linked glycosylation sites at Asn59 and Asn144 are visible in the electron density map ([Figure 3A](#fig3){ref-type="fig"}). Superposition of all Fz4~CRD~ molecules in the asymmetric units from two crystal forms revealed a well-ordered protein fold ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). The conserved disulphide bonds in Fz~CRD~ superfamily members are essential for functional activity. Familial Exudative Vitreoretinopathy disease mutant C45Y results in misfolded protein retained in the endoplasmic reticulum, similar to the effects of Cysteine-to-Alanine mutations in the related CRD of *Drosophila* Smoothened (Smo) ([@bib92]; [@bib65]). Structural comparison showed Fz4~CRD~ closely resembles the CRDs of mouse Fz8 and secreted Frizzled-related protein 3 (sFRP3) with an average r.m.s. deviation of 1.2 Å over 115 equivalent Cα atoms ([Figure 3---figure supplement 1C--E](#fig3s1){ref-type="fig"}) and approximate sequence identity of 35%. Comparisons with the CRDs of muscle-specific kinase (MuSk) and Smo showed more substantial structural differences with an average r.m.s. deviation of 2.3 Å over 86 equivalent Cα atoms ([Figure 3---figure supplement 1F--H](#fig3s1){ref-type="fig"}).10.7554/eLife.06554.010Figure 3.Crystal and solution structures of unliganded Fz4~CRD~.(**A**) Schematic domain organization (SP, signal peptide; TM. transmembrane domain; CD, cytoplasmic domain). Crystallization constructs are rainbow coloured. Disulphide bonds are drawn and blue hexagons denote N-linked glycosylation sites. Cartoon representation of Fz4~CRD~ in rainbow colouring. N-linked N-acetyl-glucosamines (GlcNAc) and disulphide bonds are shown as blue sticks. (**B**) SEC-MALS experiments. The red line represents the molecular weight (left ordinate axis) and black lines show the differential refractive index (right ordinate axis) as well as SDS-PAGE (Inset). The numbers denote the corresponding molecular weights of each peak. (**C** and **D**) SAXS analyses of deglycosylated and glycosylated Fz4~CRD~ solution structures. The experimental scattering data (black circles) and calculated scattering patterns (coloured lines) are shown and the Fz4~CRD~ solution structure model is presented. The upper right inset shows the experimental (black circles) and calculated (coloured lines) Guinier region. The dashed lines delimit the range of fitting for *R*~g~ analysis (*R*~g~·*S* ≤ 1.3). The bottom right inset shows the experimental (black circles) and calculated (coloured lines) pair distance distribution *P*(r) curve.**DOI:** [http://dx.doi.org/10.7554/eLife.06554.010](10.7554/eLife.06554.010)10.7554/eLife.06554.011Figure 3---figure supplement 1.Multiple sequence alignment and structural analysis of cysteine-rich like domains.(**A**) Secondary structure assignment colouring corresponds to [Figure 3A](#fig3){ref-type="fig"}. The conserved cysteine residues (highlighted in cyan) form five disulphide bridges, drawn in black lines and labelled as I--V. Notably, Smo has a different cysteine pair arrangement in disulphide bridge IV. Cysteine residues of Fz4 are numbered with blue filled boxes below the sequence alignment. The red boxes denote the residues of Fz4 that contact with Norrin, whereas residues of Fz8 are boxed in blue to indicate binding to Wnt8 index finger (site 2) and in yellow for interaction with Wnt8 PAM (site 1). Coloured lines indicate Fz4~CRD~ loops that interact with Norrin. The N-glycosylation sites are highlighted in green and those of Fz4 are marked by blue hexagons. The purple dots mark residues associated with human retinal diseases (missense mutations; <http://www.uniprot.org/uniprot/Q9ULV1>). Red asterisks denote the residues of Fz4 involving in GAG binding. The black arrows indicate residues potentially determining ligand-binding specificity ([Figure 9D-F](#fig9){ref-type="fig"}). Sequences are from the following UniProt entries: hFz1, Q9UP38; hFz2, Q14332; hFz3, Q9NPG1; hfz4, Q9ULV1; hfz5, Q13467; hFz6, O60353; hFz7, O75084; hfz8, Q9H461; hfz9, O00144; hfz10, Q9ULW2; sfrp1 Q8N474; sfrp2, Q96HF1; sfrp3 Q92765; sfrp4, Q6FHJ7; sfrp5, Q5T4F7; hSmo, Q99835; rMuSk, Q62838; hROR1, Q01973; hROR2, Q01974. (**B**) Superimposition of all molecules of unliganded Fz4~CRD~ (crystal form I and II) reveals no major conformational changes. The main difference between Fz4~CRD~ structures is the point at which the C-terminal region becomes disordered (black, green, and cyan arrows indicate residue 162, 165, and 172, respectively). The N-linked glycans are shown as stick models. The encircled N and C indicate the N- and C- termini. (**C--H**) Structural comparison of Fz4~CRD~ with CRDs of Fz-like proteins. Ribbon diagram of superposition of Fz4~CRD~ crystal form I (magenta) with (**C**) complexed mouse Fz8~CRD~ (cyan; PDB ID: 4F0A), (**D**) unliganded mouse Fz8~CRD~ (cyan; PDB ID: 1IJY), (**E**) mouse sFRP3~CRD~ (green; PDB ID: 1IJX), (**F**) rabbit MuSk~CRD~ (yellow; PDB ID: 3HKL), (**G**) zebrafish Smo~CRD~ (red; PDB ID: 4C79), and (**H**) drosophila Smo~CRD~ (red; PDB ID: 2MAH). (sfrp = secreted frizzled related protein; Smo = Smoothened; MuSk = muscle-specific kinase; ROR = tyrosine-protein kinase transmembrane receptor).**DOI:** [http://dx.doi.org/10.7554/eLife.06554.011](10.7554/eLife.06554.011)10.7554/eLife.06554.012Figure 3---figure supplement 2.Distinct dimeric assembly of Fz4~CRD~ and mouse Fz8~CRD~ observed from crystal structures.(**A**) The superimposition of Fz4~CRD~ structures from two crystal forms, coloured as pink and magenta for crystal form I and green and gray for crystal form II. (**B**) The structure of dimeric mouse Fz8~CRD~ (PDB: 1IJA) coloured as cyan and blue. The encircled N and C denote the N- and C-termini.**DOI:** [http://dx.doi.org/10.7554/eLife.06554.012](10.7554/eLife.06554.012)

Assessment of the monomeric states of Fz~CRD~ in solution {#s2-4}
---------------------------------------------------------

Fz receptors are members of the GPCR family ([@bib54]), known for formation of receptor dimers, although it is unclear whether dimerization is mediated by the CRD, transmembrane helices or intracellular domain. In the case of Fz4, β-galactosidase complementation in combination with bioluminescence resonance energy transfer and split-yellow fluorescence protein assays suggest that Fz4 exists as dimer on the cell membrane in the absence of Norrin or Wnts ([@bib41]; [@bib42]). However, ligand-independent receptor dimerization of Fz4 is not sufficient to activate signalling ([@bib89]; [@bib42]). Interestingly, we found that our Fz4~CRD~ structures form the same dimeric assembly in two crystal lattices (r.m.s. deviation of 0.7 Å over 238 equivalent Cα atoms from two crystal forms; [Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}). The dimer interface has an average 1330 Å^2^ buried surface area, in agreement with the characteristics of known protein--protein interfaces ([@bib45]). However, this Fz4~CRD~ dimer (front-to-front) is distinct from the previously reported crystal structure of mouse Fz8~CRD~ dimer (back-to-back; [Figure 3---figure supplement 2B](#fig3s2){ref-type="fig"}) ([@bib27]). We were therefore curious to assess the dimerization characteristics of the CRDs of Fz receptors. Size-exclusion chromatography coupled to multi-angle light scattering (SEC-MALS) results ([Figure 3B](#fig3){ref-type="fig"} and [Table 3](#tbl3){ref-type="table"}) showed Fz4~CRD~, Fz5~CRD~ and Fz8~CRD~ exist as monomers in solution at 50 μM concentration, in agreement with previously reported SEC studies of Fz8~CRD~ and SEC-MALS analyses of MuSK~CRD~ and Smo~CRD~ ([@bib78]; [@bib52]). SAXS measurements further support the conclusion that Fz4~CRD~ is monomeric in solution at 290 μM concentration ([Figure 3C,D](#fig3){ref-type="fig"}). Taken together, our results suggest that the CRDs of Fz receptors exist as monomers and may not be involved in receptor dimerization; multiple GPCRs dimerize through their hepta-helical transmembrane domains ([@bib70]). However, we cannot exclude the possibility that in the environment of the cellular membrane the weak interaction propensities of the CRDs, in combination with the transmembrane domains, are important for the dimerization of Fz receptors.10.7554/eLife.06554.013Table 3.Molecular properties of the proteins determined by SEC-MALS**DOI:** [http://dx.doi.org/10.7554/eLife.06554.013](10.7554/eLife.06554.013)ProteinNumber of N-glyc sitesN-Glyc stateMW~Theoretical~ (kDa)[‡](#tblfn10){ref-type="table-fn"}MW~Measured~ (KDa)Fz4~CRD~2deglyc[\*](#tblfn8){ref-type="table-fn"}17.1 (monomer)15.7 ± 0.4Fz4~CRD~2glyc[†](#tblfn9){ref-type="table-fn"}21.4 (monomer)23.6 ± 0.3mFz5~CRD~2glyc[†](#tblfn9){ref-type="table-fn"}22.2 (monomer)23.9 ± 0.9mFz8~CRD~2glyc[†](#tblfn9){ref-type="table-fn"}22.1 (monomer)23.7 ± 0.2Norrin--Fz4~CRD~4 (2:2 complex)deglyc[\*](#tblfn8){ref-type="table-fn"}61.3 (2:2 complex)60.1 ± 0.4Norrin--Fz4~CRD~4 (2:2 complex)glyc[†](#tblfn9){ref-type="table-fn"}69.9 (2:2 complex)61.3 ± 0.5[^12][^13][^14]

The crystal structure of Norrin in complex with Fz4~CRD~ {#s2-5}
--------------------------------------------------------

We purified Norrin--Fz4~CRD~ complex ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}) and determined the crystal structures of methylated Norrin--Fz4~CRD~ (dimethylated surface-exposed lysine residues; [Figure 4---figure supplement 1B,C](#fig4s1){ref-type="fig"}) and Norrin--Fz4~CRD~--SOS (complex bound with heparin mimic sucrose octasulfate, SOS; [Figure 4A](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}) at 2.3 Å and 3.0 Å resolution, respectively ([Table 1](#tbl1){ref-type="table"}). These two complex structures show different stoichiometries: a 2:1 complex for the methylated Norrin--Fz4~CRD~ and a 2:2:2 stoichiometry for the Norrin--Fz4~CRD~--SOS complex, the architecture of which resembles a butterfly ([Figure 4A](#fig4){ref-type="fig"}). The Norrin--Fz4~CRD~ binding interface is conserved between the complex structures ([Figure 4---figure supplement 1E](#fig4s1){ref-type="fig"}). Each Fz4~CRD~ interacts one-to-one with a separate Norrin chain, burying on average 1680 Å^2^ of surface area. To investigate the preference for complex formation in a 2:1 or 2:2 stoichiometry, we performed SEC-MALS ([Figure 4B](#fig4){ref-type="fig"}) and SAXS ([Figure 4C](#fig4){ref-type="fig"}) measurements in the absence of SOS. Both methods show Norrin interacts with Fz4~CRD~ in a 2:2 stoichiometry. Lysine methylation of the Norrin--Fz4~CRD~ complex was used to facilitate crystal lattice formation ([@bib85]; [@bib47]), and on close inspection of the structure we found Lys102 and Lys104, two residues which contribute to the Norrin--Fz4~CRD~ interface, (see next section) are dimethylated in the uncomplexed subunit of the Norrin dimer ([Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}), and contribute instead to a lattice contact. This observation suggests that the 2:1 stoichiometry merely reflects the favourable crystallization characteristics of a sub population of asymmetrically methylated Norrin--Fz4~CRD~ complexes. Thus although the methylated Norrin--Fz4~CRD~ structure usefully provides high-resolution information for the ligand--receptor interface ([Figure 4---figure supplement 1F](#fig4s1){ref-type="fig"}), the Norrin--Fz4~CRD~--SOS structure defines the overall architecture of the native complex ([Figure 4A](#fig4){ref-type="fig"}). The two Fz4~CRD~ diverge from the Norrin dimer without contacting each other ([Figure 4A](#fig4){ref-type="fig"}), and with their C-termini suitably oriented for attachment to the same cell surface.10.7554/eLife.06554.014Figure 4.Crystal structure and solution behaviour of Norrin--Fz4~CRD~ complex.(**A**) Ribbon representation of Norrin (magenta and pink) in a 2:2:2 complex with Fz4~CRD~ (cyan and pale cyan) and SOS (green). (**B**) SEC-MALS analyses. The profile of molecular weight (left ordinate axis) and differential refractive index (right ordinate axis) are shown as thick and thin lines, respectively. SDS-PAGE (Inset) shows Norrin in complex with Fz4~CRD~ (triplet band for glycosylated Fz4~CRD~, marked as green circles, represents glycosylation heterogeneity). (**C**) SAXS experiments. Experimental scattering data (black circles) and calculated scattering patterns (coloured lines) are shown to a maximal momentum transfer of q = 0.35 Å^−1^. Individual data: fit pairs are displaced along an arbitrary y axis to allow for better visualization. Bottom curve: Norrin--Fz4~CRD~ 1:2 complex crystal structure (red line). Middle curve: Norrin--Fz4~CRD~ 2:2 complex crystal structure (blue line). Top curve: modelled Norrin--Fz4~CRD~ 2:2 complex crystal structure (missing regions for Norrin and Fz4~CRD~ N- and C-termini are modeled into the crystal complex structure; green line). Structural models are shown in cartoon representation. The bottom left inset shows the experimental (black circles) and calculated (coloured lines) Guinier region. The bottom right inset shows the experimental (black circles) and calculated (coloured lines) pair distance distribution *P*(r) curves.**DOI:** [http://dx.doi.org/10.7554/eLife.06554.014](10.7554/eLife.06554.014)10.7554/eLife.06554.015Figure 4---figure supplement 1.Protein complex production and structural properties of Norrin--Fz4~CRD~ complex.(**A**) Norrin forms a stable complex with Fz4~CRD~ in solution. SEC elution profiles and SDS-PAGE under reducing condition are presented. SEC fractions analysed by SDS-PAGE are marked as red lines for Norrin--Fz4~CRD~ complex and cyan lines for uncomplexed Fz4~CRD~. (**B**) The crystal structure of methylated Norrin (pink and magenta)--Fz4~CRD~ (cyan) forms a 2:1 complex, which loses one molecule of Fz4~CRD~ during crystal lattice formation. The N-linked glycans are coloured in green. (**C**) Dimethylated lysine (MLY) residues on the protein surface of methylated Norrin--Fz4~CRD~ are shown as sphere models. Close-up view of sigmaA-weighted 2\|*F*~O~\| − \|*F*~C~\| electron density maps for MLY102 and MLY104 are contoured at 1.0 σ as blue meshes. (**D**) The sigmaA-weighted \|*F*~O~\| − \|*F*~C~\| electron density maps were calculated with omission of the SOS molecules from the refined model, followed by several cycles of refinement and contoured at 4 σ level as green meshes. (**E**) Methylated Norrin (yellow)--Fz4~CRD~ (cyan) was superposed onto the Norrin (magenta)--Fz4~CRD~ (blue)--SOS (wheat) complex using Norrin as a reference. (**F**) The overall sigmaA-weighted 2\|*F*~O~\| − \|*F*~C~\| electron density map after refinement is contoured at 1.0 σ level as blue meshes for the complex of methylated Norrin--Fz4~CRD~ (stick model).**DOI:** [http://dx.doi.org/10.7554/eLife.06554.015](10.7554/eLife.06554.015)10.7554/eLife.06554.016Figure 4---figure supplement 2.Structural comparison of cystine-knot growth factor monomers and their ternary complexes.Norrin has a unique three intermolecular disulphide bonds arrangement and a specific intramolecular disulphide bond (black dotted circle). (**A**) Cartoon representation of a single chain of cystine-knot growth factors, coloured as rainbow from blue N-terminus to red C-terminus. Each structure was superposed with the Norrin monomer and presented in the same view. (**B**) Comparison of ternary complex formation is shown as ribbon diagrams, including Norrin (dimer, magenta and pink) and Fz4~CRD~ (cyan and blue), TGF-β3 (dimer, magenta and pink) in complex with Type I (green and lemon) and Type II (blue and cyan) receptors, BMP-2 (dimer, magenta and pink) bound with Type I (green and lemon) and Type II (blue and cyan) receptors, PDGF (dimer, magenta and pink) in complex with its receptors (PDGFR; blue and cyan), VEGF-C (dimer, magenta and pink) in complex with its receptors (VEGFR-3; blue and cyan), myostatin (dimer, magenta and pink) and its antagonists (follistatin 288; blue and cyan), and BMP-7 (dimer, magenta and pink) bound with its antagonists (Noggin; orange and yellow). PDB identifiers are shown below the structural representations.**DOI:** [http://dx.doi.org/10.7554/eLife.06554.016](10.7554/eLife.06554.016)10.7554/eLife.06554.017Figure 4---figure supplement 3.No large conformational changes upon complex formation.(**A**) Structural comparisons Fz4~CRD~ (gray) from Norrin--Fz4~CRD~--SOS complex with Fz4~CRD~ (cyan) from methylated Norrin--Fz4~CRD~ and unliganded Fz4~CRD~ (magenta) crystal form II (chain D) are presented as a ribbon diagram. N-linked glycans are shown as stick models. The encircled N and C denote the N- and C-termini. (**B**) Representative Fz4~CRD~ displayed with diameter of the Cα tube defined by the B factor of the Cα atoms (small tube means structural rigidity; large tube indicates structural flexibility). Fz4~CRD~ loops for Norrin binding are highlighted as blue (loop I), green (loop II), and yellow (loop III). The flexibilities of loop I and III are reduced upon complex formation and SOS binding, respectively. (**C**) Structural comparisons of Norrin (magenta) from Norrin--Fz4~CRD~--SOS complex, Norrin (yellow) from methylated Norrin--Fz4~CRD~ and uncomplexed Norrin (blue) crystal form I (chain A and B) are shown as ribbon diagram. The cyan dotted circles denote the Fz4 binding site on Norrin. (**D**) Representative Norrin displayed according to the B factor of the Cα atoms. The SOS binding site (mainly on β5-β6 loop) becomes rigid upon SOS binding (ligand induced fit).**DOI:** [http://dx.doi.org/10.7554/eLife.06554.017](10.7554/eLife.06554.017)10.7554/eLife.06554.018Figure 4---figure supplement 4.Structural comparison of Norrin--Fz4~CRD~ complex with MBP-Norrin.(**A**) Superposition of MBP-Norrin (green; PDB ID: 4MY2) onto Norrin in the Norrin (magenta)--Fz4~CRD~ (blue)--SOS (wheat) and methylated Norrin (yellow)--Fz4~CRD~ (cyan) complex structures. (**B**) Close-up view of steric clashes (indicated by a red arrow) between Fz4~CRD~ and MBP.**DOI:** [http://dx.doi.org/10.7554/eLife.06554.018](10.7554/eLife.06554.018)

The Norrin--Fz4~CRD~ complex has a novel architecture; the mode of interaction of Norrin is distinct from that of other cystine-knot secreted growth factors (transforming growth factor-β, bone morphogenetic protein, platelet-derived growth factor, and vascular endothelial growth factor) with either their receptors or antagonists ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}).

Neither Norrin nor Fz4~CRD~ undergoes large conformational changes upon complex formation, although the flexibility of residues involved in the binding interface is reduced ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}). Interestingly, superposition of the Norrin--Fz4~CRD~ complex and the previously reported MBP-Norrin structure resulted in steric clashes between the Fz4~CRD~ and the MBP ([Figure 4---figure supplement 4](#fig4s4){ref-type="fig"}). This suggests that MBP hinders Norrin interaction with Fz4~CRD~ consistent with MBP-Norrin only having half of the signalling activity of untagged Norrin ([@bib42]).

Analyses of binding interfaces {#s2-6}
------------------------------

At the ligand--receptor interface ([Figure 5A](#fig5){ref-type="fig"}) two β-hairpins in Norrin (β1-β2 and β5-β6) contact three loops in Fz4~CRD~ (I, II, and III). Fz4~CRD~ loop I hydrogen bonds to Norrin ([Figure 5B](#fig5){ref-type="fig"}). Fz4~CRD~ loop II makes extensive hydrophobic contacts plus one salt-bridge (Fz4~CRD~ Lys109 with Norrin Asp46; [Figure 5C](#fig5){ref-type="fig"}). Fz4~CRD~ loop III interacts with Norrin via an extensive hydrogen bond network as well as hydrophobic contacts ([Figure 5D](#fig5){ref-type="fig"}). Interactions with SOS involve the positively charged residues of Lys58, Arg107, Arg109, and Arg115 on Norrin, plus His154 and Asn155 on Fz4~CRD~ loop III ([Figure 5E](#fig5){ref-type="fig"}). These residues define a likely binding site for GAGs, in agreement with previous reports of Norrin interactions with extracellular matrix and heparin ([@bib89]; [@bib57]).10.7554/eLife.06554.019Figure 5.Structural details of binding sites in the Norrin--Fz4~CRD~--SOS complex.(**A**) Side-view of complex. Fz4~CRD~ loops involved in Norrin binding are coloured blue (loop I), green (loop II), and yellow (loop III). (**B--E**) Views detailing the interfaces. Selected residues involved in binding are shown as sticks and coloured magenta (Norrin), blue (loop I), green (loop II), yellow (loop III), and cyan (Phe96 of Fz4~CRD~) and those associated with disease mutations are highlighted in boxes. Dotted lines denote hydrogen bonds. (**B**) Interactions between Fz4~CRD~ loop I and Norrin. (**C**) Hydrophobic interactions of Norrin with Fz4~CRD~ loop II and part of loop III. (**D**) Interactions of Fz4~CRD~ loop III with Norrin. (**E**) SOS binding to Norrin and Fz4~CRD~ loop III.**DOI:** [http://dx.doi.org/10.7554/eLife.06554.019](10.7554/eLife.06554.019)

Verification of Fz4 binding site {#s2-7}
--------------------------------

The Norrin--Fz4 interface revealed in our crystal structures ([Figure 6A,B](#fig6){ref-type="fig"}) is in excellent agreement with reported disease-associated mutations ([Figure 6C](#fig6){ref-type="fig"}) and surface residue conservation ([Figure 6D](#fig6){ref-type="fig"}). We performed mutagenesis and functional assays to verify this Fz4 binding site. Surface plasmon resonance (SPR) experiments ([Figure 6E](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}) show a micromolar equilibrium dissociation constant between Norrin and Fz4~CRD~. Mutations of either H43N/V45T or L61N/A63S, which resulted in the introduction of an N-linked glycosylation site in the Fz4 binding site on Norrin, completely abolish the interaction ([Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}). Norrin disease-associated mutants V45E and L61P/A63D lose binding affinity for Fz4~CRD~ ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}), as do mutants R41E/H43E and R38E/R41S/H43E/K102E/K104E ([Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}). In contrast, Norrin mutants L52N/K54S and M114N/L116S (to introduce an N-linked glycosylation site in the β1-β2 loop or β5-β6 loop, respectively), predicted to lie outside the Fz4 binding site ([Figure 6A](#fig6){ref-type="fig"}), show the same binding affinity as wild-type ([Figure 6---figure supplement 1E](#fig6s1){ref-type="fig"}). Cell-based Wnt/β-catenin responsive luciferase assays ([Figure 6F](#fig6){ref-type="fig"}) further support the significance of the Fz4 binding site. Norrin mutants that lose binding to Fz4~CRD~ also fail to induce the luciferase reporter activity, in agreement with the SPR results ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}) and prior genetic data ([@bib89]; [@bib77]). Taken together, our structural and functional results suggest that Norrin uses β strands (β1-β2 and β5-β6) for Fz4~CRD~ binding rather than, as proposed by [@bib12] using the loop between β1 and β2 ([@bib12]).10.7554/eLife.06554.020Figure 6.Biophysical and functional characterisation of Fz4 binding site.Surface representation of Norrin--Fz4~CRD~ complex in open book view. (**A**) Interface residues are coloured orange (Norrin) and blue (loop I), green (loop II), yellow (loop III), and cyan (Phe96) on Fz4~CRD~. Norrin mutation sites used in functional assays are labelled (red, residues involved in Fz4~CRD~ binding; grey filled box, residues associated with diseases; black, residues located outside the Fz4 binding site). (**B**) Norrin and Fz4~CRD~ coloured by electrostatic potential from red (acidic; −7 *k*~b~*T*/*e*~c~) to blue (basic; 7 *k*~b~*T*/*e*~c~). (**C**) Disease-associated mutations mapped onto the surface of Norrin and Fz4~CRD~ (purple, missense mutations; red, missense mutations of cysteine residues). (**D**) Surfaces colour-coded according to sequence conservation from white (not conserved) to black (conserved). (**E**) SPR results for Fz4~CRD~ binding to Norrin wild-type (WT) and Norrin V45E mutant. Inset SPR sensorgrams are of equilibrium-based binding assays with reference subtraction. (**F**) Luciferase reporter assays histograms with *K*d values from SPR measurements ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}) shown above. Residues involved in the Fz4~CRD~ binding site are coloured red. Residues without contact with Fz4~CRD~ are coloured black. Grey filled boxes highlight disease-associated residues ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). The luciferase activities were normalized to a maximum activity value (100%) for Norrin wild-type and error bars represent standard deviations (n = 3).**DOI:** [http://dx.doi.org/10.7554/eLife.06554.020](10.7554/eLife.06554.020)10.7554/eLife.06554.021Figure 6---figure supplement 1.SPR equilibrium binding data.SPR equilibrium binding experiments using Fz4~CRD~ as analyte and biotinylated human Norrin wild-type (WT) and mutants as immobilized ligands on CM5 sensor chips. SPR sensorgrams (left panels) and fitted plots of equilibrium binding response (right panels; 1:1 Langmuir binding model) against a series of concentrations of Fz4~CRD~ are shown. The binding parameters are shown as Surface (the amounts of biotinylated Norrin coated onto sensor chip), *B*~max~ (the maximum response), *K*d (binding constant), and RU (response unit). N/A indicates not applicable for calculation of *K*d. Residues associated with diseases are highlighted as filled grey boxes. (**A**) The interaction of Norrin wild-type with Fz4~CRD~ has a *K*d of 1.1 μM. (**B**) Introduction of an N-linked glycosylation site on the Fz4 binding site of Norrin results in the complete loss of Fz4~CRD~ binding. (**C**) Norrin mutants identified from diseases show no binding to Fz4~CRD~. (**D**) Mutations designed to disrupt the hydrogen bond and salt bridge interactions of the Fz4 binding site completely abolish binding to Fz4~CRD~. (**E**) Introduction of an N-linked glycosylation site on the Norrin surface locating outside the Fz4 binding site does not affect the binding affinity of Norrin to Fz4~CRD~. (**F**) Norrin discriminates between different Fz~CRD~ proteins. Biotinylated human Norrin was immobilized onto a CM5 sensor chip to give 410 response units (RU) and different Fz~CRD~ proteins were used as analytes. The injected human Fz4~CRD~ proteins have a concentration ranging from 2.3 nM to 75 μM. Other Fz~CRD~ concentrations ranged from 0.3 μM to 150 μM (mouse Fz5~CRD~) or 0.2 μM--100 μM (human Fz7~CRD~ and mouse Fz8~CRD~). Because of the limitations of detection, the *K*d values of Fz5~CRD~ and Fz8~CRD~ are too low to measure accurately, resulting in variable standard deviations. The binding affinity of Fz7~CRD~ to Norrin is not sufficient to calculate a *K*d.**DOI:** [http://dx.doi.org/10.7554/eLife.06554.021](10.7554/eLife.06554.021)

To determine the binding affinity of Norrin for different CRD of Fz receptors, we undertook a series of SPR experiments. The results ([Figure 6---figure supplement 1F](#fig6s1){ref-type="fig"}) show that Norrin has greatest affinity for Fz4~CRD~ (*K*d: 1 μM), low affinities for Fz5~CRD~ (*K*d: 42 μM) and Fz8~CRD~ (*K*d: 64 μM), and no binding to Fz7~CRD~. In combination, these results confirm that pairing Norrin with Fz4~CRD~ provides selective and high affinity binding relative to interactions with other CRD of Fz receptors, in agreement with prior studies ([@bib89]; [@bib77]; [@bib42]). However, it remains to be clarified whether the low affinity interactions of Norrin with other Fz receptors can play any functional role in vivo.

Verification of GAG binding site {#s2-8}
--------------------------------

To assess our putative binding site for GAGs ([Figure 5E](#fig5){ref-type="fig"}), we performed structure-guided mutagenesis and functional studies. Our heparin binding experiments confirmed that Norrin shows high affinity interaction with heparin ([Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}), consistent with previous studies ([@bib60]; [@bib89]; [@bib77]; [@bib57]), and further demonstrated Norrin--Fz4~CRD~ complex binding to heparin ([Figure 7A](#fig7){ref-type="fig"}). The Norrin triple mutation R107E/R109E/R115L (R115L is a disease-associated mutation; [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}) impaired heparin binding ([Figure 7B](#fig7){ref-type="fig"}) and abolished signalling activity ([Figure 7C](#fig7){ref-type="fig"}). However, this mutant protein retained the ability to bind Fz4~CRD~ ([Figure 7D](#fig7){ref-type="fig"}) with a 2:2 stoichiometry ([Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}). [@bib42] have reported MBP-Norrin binding to the Lrp6 ectodomain fragment comprising the first two tandem β-propeller-epidermal growth factor-like domain pairs (Lrp6~P1E1P2E2~; [@bib42]); we found both our wild-type and R107E/R109E/R115L mutant Norrin bind to Lrp6~P1E1P2E2~ ([Figure 7E,F](#fig7){ref-type="fig"}). The Norrin K58N mutant (a disease-associated mutation; [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}) exhibited half of wild-type activity in our cell-based assay ([Figure 7C](#fig7){ref-type="fig"}), but did not affect Fz4~CRD~ interaction ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}). These results are in agreement with previous functional studies ([@bib77]), and suggest this area is a GAG binding site rather than that, as [@bib42] proposed, residues Arg107, Arg109, and Arg115 are involved in Lrp5/6 binding ([@bib42]). HSPGs play important roles in the regulation of the Wnt signalling pathway ([@bib48]). Wnt signalling activity can be inhibited by treatment with exogenous heparin ([@bib4]). Also, [@bib36] have reported that PG545, a heparan sulphate mimetic, can block Wnt binding to the cell surface, by competing with endogenous HSPGs, and inhibit Wnt signalling ([@bib36]). For Norrin mediated Wnt/β-catenin signalling, we found that SOS could inhibit activity when pre-incubated with Norrin before stimulation of reporter cells ([Figure 7---figure supplement 1D](#fig7s1){ref-type="fig"}).10.7554/eLife.06554.022Figure 7.Verification of Norrin GAG binding site.Heparin affinity chromatography of (**A**) Norrin--Fz4~CRD~ complex and (**B**) Norrin R107E/R109E/R115L--Fz4~CRD~ complex. Protein elution profiles (left panel) were monitored by absorbance at 280 nm (blue curves) for a NaCl gradient (0.25--2 M; black dashed lines). Input sample, flow-through (green line) and peak fractions (red line) were analysed on SDS-PAGE (right panel). Norrin-Fz4~CRD~ complex was eluted at 1.3 M NaCl concentration. (**C**) Luciferase reporter assays for Norrin mutations (coloured green) in the GAG binding site. Grey filled boxes highlight disease-associated residues ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). (**D**) SPR binding assay of Norrin R107E/R109E/R115L mutant and Fz4~CRD~ interaction. Sensorgrams (top panel) and fitted plots of equilibrium binding response (bottom panels) for a series of concentrations of Fz4~CRD~ are shown. (**E** and **F**) SPR equilibrium binding experiments of Lrp6~P1E1P2E2~ binding to Norrin wild-type and R107E/R109E/R115L mutant, respectively. Biotinylated Norrin proteins were immobilized on a CM5 chip and Lrp6~P1E1P2E2~ as analyte was injected over the chip. Sensorgrams (top panel) and fitted plots (bottom panels) for a series of concentrations of Lrp6~P1E1P2E2~ are presented.**DOI:** [http://dx.doi.org/10.7554/eLife.06554.022](10.7554/eLife.06554.022)10.7554/eLife.06554.023Figure 7---figure supplement 1.Supporting experiments for GAG binding site.(**A**) Heparin affinity chromatography of Norrin wild-type. Protein elution profiles (left panel) were monitored by absorbance at 280 nm (blue curves) for a NaCl gradient (0.25--2 M; black dashed lines). An input sample, flow-through (green line) and peak fractions (yellow and red lines) are analysed on SDS-PAGE (right panel). Norrin wild-type was eluted with 1.6 M NaCl concentration. (**B**) SEC-MALS experiments for Norrin R107E/R109E/R115L--Fz4~CRD~ complex. The red line represents the molecular weight (left ordinate axis) and blue lines show the differential refractive index (right ordinate axis). (**C**) In SPR equilibrium binding experiments, biotinylated human Norrin K58N proteins were coated onto a CM5 sensor chip and a series of concentrations of Fz4~CRD~ were injected over the chip as analyte. Graphs show sensorgrams (left panels) and fitted plot (right panels). (**D**) Luciferase reporter assay of SOS inhibition. The luciferase reporter activities were normalized to a maximum activity value of 100%, using Norrin wild-type as reference. Error bars indicate standard deviations (n = 3).**DOI:** [http://dx.doi.org/10.7554/eLife.06554.023](10.7554/eLife.06554.023)

Mapping a potential Lrp5/6 binding site on Norrin {#s2-9}
-------------------------------------------------

Norrin interaction with co-receptor Lrp5/6~ECD~ ([Figure 7E](#fig7){ref-type="fig"}) is essential for signal activation ([@bib89]; [@bib42]). To identify Norrin residues potentially involved in Lrp5/6~ECD~ binding, we assessed solvent exposure, disease-association, and lack of involvement in Fz4~CRD~ or GAG binding ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). Five residues (Lys54, Arg90, Arg97, Gly112, and Arg121) were highlighted by this analysis and form a continuous, positively charged, concave patch ([Figure 8A](#fig8){ref-type="fig"}). Notably, a negatively charged region of the Lrp6~ECD~ surface has been implicated in ligand binding ([@bib3]; [@bib15]; [@bib19]; [@bib22]). We therefore focused on the positively charged concave surface of Norrin as a potential Lrp5/6 binding site ([Figure 8A](#fig8){ref-type="fig"}), interestingly, this putative binding site has a partially overlap, at Lys54, with the residue suggested to be involved in Lrp5/6 interaction by [@bib42]. To test our proposed location for the Lrp5/6 binding site, we generated the disease-associated Norrin mutant R121W (Arg121 is a mutational hotspot; [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). This mutation substantially impairs signalling activity ([Figure 8---figure supplement 1A](#fig8s1){ref-type="fig"}), but retains the ability to interact with Fz4~CRD~ ([Figure 8---figure supplement 1B](#fig8s1){ref-type="fig"}) and heparin ([Figure 8---figure supplement 1C](#fig8s1){ref-type="fig"}). However, we found the R121W mutation reduced protein solubility and stability during protein production and in heparin binding assays. Analyses of additional Norrin mutants in biophysical and cellular assays will be required to verify the putative Lrp5/6 binding site. Taken together, the current data suggest three distinct and independent binding sites on Norrin for Fz4, Lrp5/6, and GAGs ([Figure 8B](#fig8){ref-type="fig"}). This arrangement of binding sites likely enables Norrin to form a ternary complex.10.7554/eLife.06554.024Figure 8.The potential Lrp5/6 binding site on Norrin.(**A**) Cartoon representation of Norrin (grey) in complex with Fz4~CRD~ (cyan). Residues in the potential Lrp5/6 binding site are shown as spheres (atom colouring: magenta, carbon; blue, nitrogen; red, oxygen). The boxes highlight residues associated with disease mutations. (**B**) Cartoon model of Norrin showing three distinct binding sites.**DOI:** [http://dx.doi.org/10.7554/eLife.06554.024](10.7554/eLife.06554.024)10.7554/eLife.06554.025Figure 8---figure supplement 1.Verification of Norrin potential Lrp5/6 binding site.(**A**) Luciferase reporter assay. The luciferase activities were normalized to a maximum activity value (100%) for Norrin wild-type and error bars represent standard deviations (n = 3). (**B**) SPR binding assay of Norrin mutant R121W. Biotinylated Norrin mutant R121W was coated onto a CM5 sensor chip and a series of concentrations of Fz4~CRD~ as analyte were injected over the chip. Graphs show sensorgrams (top panels) and fitted plot of equilibrium binding response (bottom panels). (**C**) Heparin binding assay of Norrin mutant R121W. Protein elution profiles (left panel) were monitored by absorbance at 280 nm (blue curves) for a NaCl gradient (0.25--2 M; black dashed lines). An input sample, flow-through (green line) and peak fractions (yellow and red lines) are analysed on SDS-PAGE (right panel). Norrin mutant R121W was eluted at 1.5 M NaCl concentration. Notably, we found almost 50% of the Norrin mutant R121W precipitated as the NaCl concentration was reduced before injection for heparin affinity chromatography (see 'Materials and methods' for detailed information).**DOI:** [http://dx.doi.org/10.7554/eLife.06554.025](10.7554/eLife.06554.025)

Structural comparison of Norrin--Fz4~CRD~ with Wnt8--Fz8~CRD~ {#s2-10}
-------------------------------------------------------------

As Norrin and Wnt both trigger the canonical Wnt/β-catenin pathway, we compared their modes of action. *Xenopus* Wnt8 ([Figure 9A](#fig9){ref-type="fig"}) has been described as using 'thumb' and 'index finger' regions to grasp mouse Fz8~CRD~ at two distinct sites ([@bib35]). In site 1, a palmitoleoyl group (PAM) covalently linked to the tip of the thumb inserts into a groove in Fz8~CRD~, removal of this PAM moiety suppresses Wnt signalling activity ([@bib39]; [@bib93]). In site 2, the index finger contacts a hydrophobic pocket. We superposed Norrin--Fz4~CRD~ with Wnt8--Fz8~CRD~. There are no major structural differences between the Fz4~CRD~ and Fz8~CRD~ (r.m.s. deviation of 1.3 Å over 110 equivalent Cα atoms; [Figure 9A](#fig9){ref-type="fig"}), and the structural elements that mediate site 1 PAM binding in Fz8~CRD~ are largely conserved in Fz4~CRD~ ([Figure 9B](#fig9){ref-type="fig"}). The Norrin binding site on Fz4~CRD~ (∼800 Å^2^ buried area) overlaps with site 2 on Fz8~CRD~ (∼400 Å^2^ buried area; [Figure 8A](#fig8){ref-type="fig"}), in agreement with previous mutational mapping studies ([@bib77]). The position of the Wnt8 index finger overlaps with Norrin β1 and β2, and, unexpectedly, these β strands show some structural equivalence with Wnt8 ([Figure 9C](#fig9){ref-type="fig"}). Site 2 Wnt8 residues are strictly conserved in all Wnts, and the apolar residues in the corresponding positions on Norrin are associated with disease mutations ([Figure 9C](#fig9){ref-type="fig"}).10.7554/eLife.06554.026Figure 9.Structural comparison of Norrin--Fz4~CRD~ with Wnt8--Fz8~CRD~.(**A**) Superposition of Norrin (magenta)--Fz4~CRD~ (cyan) with Wnt8 (green)--Fz8~CRD~ (blue) (PDB ID: 4F0A). Disulphide bonds, N-linked glycans, and PAM (of Wnt8) are shown as sticks. SOS is shown as grey surface. (**B**) Comparison of site 1 (PAM binding) on Fz4~CRD~ (cyan) and Fz8~CRD~ (blue). Fz4 His69 is disease associated. (**C**) The Wnt8 index finger (site 2; green) structurally overlays Norrin (β1 and β2; magenta). Norrin residues associated with diseases are boxed. (**D--F**), Structural comparison of Fz4~CRD~ and Fz8~CRD~ for ligand binding. Loop I-III residues for Fz4~CRD~ and Fz8~CRD~ are shown as sticks. Fz8~CRD~ residues for Wnt8 binding (site 2) are boxed in purple. Fz4 disease-associated residues are boxed. Red arrows indicate residue substitutions between Fz4~CRD~ and Fz8~CRD~. Fz8~CRD~ residues Tyr151 and Asn152 are modelled as alanines (PDB ID: 4F0A).**DOI:** [http://dx.doi.org/10.7554/eLife.06554.026](10.7554/eLife.06554.026)

We also used our superposition of the Fz4~CRD~ and Fz8~CRD~ structures ([Figure 9A](#fig9){ref-type="fig"}) to identify the determinants of the Norrin binding specificity for Fz4~CRD~ ([Figure 6---figure supplement 1F](#fig6s1){ref-type="fig"}). In Fz4~CRD~ loop I ([Figure 9D](#fig9){ref-type="fig"}), Asn55 is replaced by Fz8~CRD~ Gly45, a change that would abolish interaction with Norrin Ser34 in the complex ([Figure 5B](#fig5){ref-type="fig"}). In Fz4~CRD~ loop II ([Figure 9E](#fig9){ref-type="fig"}), the substitution of Lys109 by Fz8~CRD~ Asp99 would introduce an unfavorable electrostatic interaction with Norrin Asp46 ([Figure 5C](#fig5){ref-type="fig"}). Thirdly, in Fz4~CRD~ loop III ([Figure 9F](#fig9){ref-type="fig"}), hydrogen bonds and salt bridges to Norrin would be lost on replacing Asn152 and Glu160 with Fz8~CRD~ Gly142 and Asp150 respectively ([Figure 5D](#fig5){ref-type="fig"}). Consistent with this analysis, these residue substitutions have been reported to affect Fz4~CRD~ binding to Norrin ([@bib77]), and Fz4~CRD~ is unique in containing this particular combination of residues ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}).

Discussion {#s3}
==========

Overall, our analyses provide several advances for our understanding of Norrin and Wnt signalling. Firstly, our results give fresh insight into the role of HSPGs. HSPGs have been proposed to regulate the local distribution of ligand and receptor at the cell surface, potentially acting as an introductory agency for ligand and receptor ([@bib46]; [@bib9]; [@bib47]; [@bib48]). We have discovered a GAG binding site that may span Norrin and Fz4~CRD~ ([Figure 5E](#fig5){ref-type="fig"}). Interestingly, [@bib77] found the binding affinity of Norrin with Fz4~CRD~ is enhanced in the presence of heparin ([@bib77]). We propose that the extended GAG binding site may allow co-receptor HSPGs to recruit secreted Norrin for interaction with Fz4~CRD~ and to co-localize Norrin and Fz4 receptor, similar to the role of HSPGs in Wnt signalling ([@bib68]; [@bib9]; [@bib31]). For example, HSPGs have been shown to regulate the Wnt morphogenetic gradient ([@bib46]; [@bib10]). Also, [@bib17] have reported that Fz4~CRD~ binds to the GAGs of the human HSPG Glypican-3 and that these interactions are involved in Wnt signal complex formation ([@bib17]). Secondly, we show the Norrin dimer binds separately to two molecules of Fz4~CRD~ ([Figure 4](#fig4){ref-type="fig"}), in contrast to the 1:1 complex of Wnt8--Fz8~CRD~ ([@bib35]). Our discovery of the Fz4 and GAG binding sites, and analysis of a potential Lrp5/6 binding region, maps out distinct binding surfaces on Norrin ([Figure 8B](#fig8){ref-type="fig"}), which provide a framework in which to understand the effects of inherited mutations and probe the overall architecture of the ternary complex (Norrin--Fz4~CRD~--Lrp5/6~ECD~). Thirdly, we determine how Norrin structurally mimics Wnt for site 2 binding surfaces on the Fz ectodomain ([Figure 9A](#fig9){ref-type="fig"}). Interestingly, previous analyses using water-soluble 'mini-Wnt' proteins, which cannot contribute site 1 binding, have raised the possibility that site 2 binding to the CRD of Fz receptors can activate canonical Wnt/β-catenin signalling albeit weakly ([@bib35]; [@bib83]). Our findings indicate that the site 2 binding mode is central to signallosome formation for Norrin mediated signalling.

We used SPR experiments to establish the binding affinity for Norrin--Fz4~CRD~ complex formation. The *K*d value of 1.1 μM for the interaction between Norrin and Fz4~CRD~ we report here ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}) is weaker than previously published results ([@bib89]; [@bib42]). This discrepancy is likely due to our SPR binding assays being carried out with monomeric Fz4~CRD~. [@bib89] used an enzyme-linked immunosorbent assay to give an affinity of 3--4 nM for mouse Norrin fused with C-terminal alkaline phosphatase binding to mouse Fz4~CRD~ dimerized by a C-terminal Fc fusion ([@bib89]). [@bib42] reported *K*d values of 11 nM and 5 nM for the interaction between MBP-Norrin and Fc-tagged dimeric Fz4~CRD~ using an AlphaScreen luminescence assay and biolayer interferometry, respectively ([@bib42]). It is noteworthy that as Fc-dimerized Fz4~CRD~ may mimic Fz4 receptor dimerization at the cellular surface, these tighter binding affinities may be more indicative of Norrin binding in the physiologically relevant environment. Similarly, our *K*d value of 2.87 μM for Norrin binding to Lrp6~P1E1P2E2~ in an SPR based assay ([Figure 7E](#fig7){ref-type="fig"}) differs from the *K*d value of 0.45 μM reported by [@bib42] based on an homologous AlphaScreen competition assay using unlabeled MBP-Norrin against biotinylated MBP-Norrin for interaction with Lrp6~P1E1P2E2~ ([@bib42]).

Our studies reported here, in combination with previous findings for Norrin and Wnt signalling, are consistent with Norrin-induced receptor clustering and signallosome formation. Inactive pre-dimerized Fz4 may engage with homodimeric Tspan-12 to enhance receptor clustering ([@bib41]; [@bib42]). Norrin binding generates ternary complex formation by Fz4, Lrp5/6 and the GAGs of HSPGs to trigger signalling, which is enhanced in the presence of Tspan12. In the cytoplasm, Dishevelled binds to the C-terminal tail of Fz4 and self-assembles to oligomer ([@bib73]), leading to Axin recruitment to the cytoplasmic domain of Lrp5/6 for phosphorylation and signallosome formation ([@bib14]).

Previously reported mice genetic studies have demonstrated that expression of ectopic Norrin can rescue pathological retinal vascularization ([@bib56], [@bib57]). In addition, the pathological progresses of Norrie disease and familial exudative vitreoretinopathy are highly related to age-related macular degeneration and diabetic retinopathy ([@bib91]; [@bib58]). Further investigation of the therapeutic possibilities for retinal diseases has been hampered by the difficulty of producing recombinant Norrin proteins. In this study, we provide a method to produce fully active untagged Norrin in mammalian cells ([Figure 1](#fig1){ref-type="fig"}). Our recombinant Norrin opens up new avenues to explore for the treatment of genetic retinal diseases and other ophthalmic disorders.

More generally, Norrin as a Wnt mimic, may have potential as a reagent in regenerative medicine ([@bib23]).

Wnt signalling is important for tissue homeostasis throughout life ([@bib24]). Multiple Wnt extracellular antagonists function to modulate Wnt signalling ([@bib48]), these include Dickkopf and Sclerostin, which bind to Lrp5/6, as well as Wnt inhibitory 1 and sFRPs, which sequester Wnt. Aberrant Wnt signalling (insufficient or excessive) is implicated in diseases such as neurodegeneration and tumorigenesis, respectively ([@bib24]; [@bib5]). Interestingly, our Norrin mutants (used to verify the GAG and putative Lrp5/6 binding sites) retain Fz4~CRD~ binding but lose the ability to activate signalling. These properties are similar to those of the monoclonal antibody OMP-18R5 which can bind to the CRDs of Fz1, 2, 5, 7 and 8. OMP-18R5 inhibits tumour growth ([@bib32]) and has just completed phase I clinical trials ([@bib38]). Engineered Norrin mutants could similarly serve as blocking agents, but with specificities tailored to target Fz4 or other individual Fz receptors.

Materials and methods {#s4}
=====================

Construct design, cloning, and mutagenesis {#s4-1}
------------------------------------------

Synthetic complementary DNA (cDNA) clones (codon-optimized for expression in mammalian cells) of human Norrin (UniprotKB/Swiss-prot Q00604) were obtained from GeneArt (Life Technologies, UK). The cDNA templates of human receptors Fz4 (IMAGE ID: 40082087), Fz7 (IMAGE ID: 4549389), Lrp6 (IMAGE ID: 40125687), and Tspan-12 (IMAGE ID: 5275953) and mouse receptors Fz5 (IMAGE ID: 40088671) and Fz8 (IMAGE ID: 8861081) were purchased from SourceBioScience (UK). All expression constructs reported here are derived from the pHLsec vector backbone ([@bib6]). The human Norrin wild-type (residues 25--133) construct of SUMO-Norrin ([Figure 1A](#fig1){ref-type="fig"}) and Norrin mutant constructs for heparin affinity binding assays were tagged N-terminally with the murine Igκ-chain secretion signal, followed by a Strep-II tag, 8xHis tag, a mammalian expression codon-optimized *Saccharomyces cerevisiae* SUMO (UniprotKB/Swiss-prot Q12306; residues 2--96) ([@bib62]), and a Human Rhinovirus (HRV)-3C protease cleavage site. They were tagged C-terminally with a TETSQVAPA sequence derived from bovine rhodopsin (Rho-1D4) that is recognized by the Rho-1D4 monoclonal antibody ([@bib50]). The construct of Norrin (residues 25--133) was cloned into the pHLsec vector ([@bib6]) in frame with a C-terminal Rho-1D4 ([Figure 1A](#fig1){ref-type="fig"}). For large-scale protein expression, the CRD constructs for human Fz4 (residues 42--179) and Fz7 (residues 42--179) as well as mouse Fz5 (residues 31--176) and Fz8 (residues 30--170) were cloned into a modified pHLsec vector (pHLsec-mVenus-12H), containing a C-terminal HRV-3C protease cleavage site followed by a linker, monoVenus ([@bib53]), and a tandem 6×His tag. Human Lrp6~P1E1P2E2~ (residues 1--631) construct was cloned into a modified vector for stable cell line generation, pNeoSec ([@bib94]), in frame with a C-terminal 10×His tag. For luciferase reporter assays, the full-length constructs of the human receptors Fz4 (residues 1--537), Lrp6 (residues 1--1613), and Tspan-12 (residues 1--305) were cloned into the pLEXm-1D4 vector carrying a C-terminal Rho-1D4 tag. Norrin wild-type and mutants for biophysical and cellular assays were obtained from GeneArt (Life Technologies, UK) and cloned into the pHL-Avitag3 vector encoding a C-terminal BirA recognition sequence ([@bib6]). Mutant proteins were secreted at similar levels to the wild-type proteins. Constructs were verified by DNA sequencing (Source Bioscience, UK).

Western blot assays {#s4-2}
-------------------

For western blot, HEK293T (ATCC CRL-11268) cells were transfected with the DNA using Lipofectamine 2000 (Life Technologies, UK) according to the manufacturer\'s instructions. The conditioned media were collected 2 days post transfection and were analysed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels transferred onto a nitrocellulose membrane (GE Healthcare Life Sciences) with Rho-1D4 monoclonal antibodies (Flintbox, University of British Columbia, Canada) as primary antibody and goat anti-mouse IgG-horseradish peroxidise conjugate (Sigma). The signal was visualized by Enhanced Chemiluminescence western blotting detection kit (ECL, GE Healthcare Life Sciences).

Protein production and purification {#s4-3}
-----------------------------------

Norrin wild-type and mutants were expressed in HEK293T cells ([@bib6]) in the presence of 4 mM valproic acid ([@bib8]). For crystallization experiments, Fz4~CRD~ was produced in HEK293T cells in the presence of 5 μM of the class I α-mannosidase inhibitor, kifunensine ([@bib18]). Norrin in complex with Fz4~CRD~ was co-expressed in HEK293T cells in the presence of kifunensine and valproic acid. For all other experiments, recombinant proteins were expressed in HEK293T cells. The Norrin conditioned media were passed through 1D4-affinity beads covalently coupling purified Rho-1D4 antibody to CnBr-activated Sepharose 4 Fast Flow (CnBr-1D4; GE Healthcare Life Sciences) and eluted in 25 mM Tris, pH 7.5, 0.5 M NaCl, 10% (wt/vol) Glycerol, 0.5% (wt/vol) CHAPS, 250 μM TETSQVAPA peptide (GenScript). The eluted sample was incubated with Glutathione S-Transferase (GST)-tagged HRV-3C protease to remove the SUMO-tagged fusion protein. The cleaved Norrin was purified by CnBr-1D4 followed by SEC (Superdex 200 10/300 GL High Performance, GE Healthcare Life Sciences) in either 10 mM HEPES, pH 7.5, 0.7 M NaCl, 0.5% (wt/vol) CHAPS or acetate buffer, pH 4.0, 0.5 M NaCl, 0.5% (wt/vol) CHAPS. For purification of Fz4~CRD~, the conditioned media were dialyzed and recombinant proteins were purified by IMAC (TALON beads, Clontech, Mountain View, CA). The purified sample was dialyzed against 25 mM Tris, pH 7.5, 0.5 M NaCl, 10% (wt/vol) Glycerol and treated with GST-tagged *Flavobacterium meningosepticum* endoglycosidase-F~1~ (Endo-F~1~) ([@bib18]) and His-tagged HRV 3C protease. The deglycosylated and cleaved sample was further purified by IMAC and further polished by SEC (Superdex 75 16/600 column, GE Healthcare Life Sciences) in 10 mM HEPES, pH 7.5, 0.15 M NaCl. Purification of Fz5~CRD~, Fz7~CRD~, and Fz8~CRD~ followed the same procedure to that described above, except protein was expressed in HEK293T cells and the treatment by Endo-F~1~ was omitted. Norrin--Fz4~CRD~ complex was isolated from dialyzed conditioned media by IMAC. The eluted sample was dialyzed and treated with GST-tagged HRV-3C protease and Endo-F~1~. The deglycosylated and cleaved complex was further purified by IMAC and GST-affinity beads and subsequently isolated by SEC (Superdex 200 16/600 column, GE Healthcare Life Sciences) in 10 mM HEPES, pH 7.5, 0.7 M NaCl. For preparation of methylated proteins, the purified sample was subject to surface lysine methylation ([@bib85]) and further purified by SEC (Superdex 200 16/600 column, GE Healthcare Life Sciences). The selenomethionine (Se-Met) labelled protein was prepared as described previously ([@bib6]). A stable HEK293 GnT1(−) cell line ([@bib66]) for Lrp6~P1E1P2E2~ protein production was generated as reported previously ([@bib94]) and protein was purified following our established procedure ([@bib19]).

Crystallization and data collection {#s4-4}
-----------------------------------

Concentrated proteins (Norrin, 5 mg/ml; Fz4~CRD~, 60 mg/ml; Norrin in complex with Fz4~CRD~ including native and methylated proteins, 10--12 mg/ml) were subjected to sitting drop vapor diffusion crystallization trials in 96-well Greiner plates consisting of 100 nl protein solution and 100 nl reservoir using a Cartesian Technologies dispensing instrument ([@bib84]). Crystallization plates were placed in a The Automation Partnership storage vault maintained at 294 K and imaged via a Veeco visualization system. Methylated Norrin--Fz4~CRD~ complex crystallized in 0.1 M Bicine, pH 9.0, 10% (wt/vol) PEG6000, Norrin crystal form I in 0.1 M sodium acetate, pH 5.0, 5% (wt/vol) PGA-LM, 30% (wt/vol) PEG550MME, Norrin crystal form II in 0.1 sodium acetate, pH 5.0, 5% (wt/vol) PGA-LM, 4% (wt/vol) PEG2000MME, 24% (wt/vol) PEG550MME, Norrin crystal form III in 0.1M citrate, pH 5.0, 30% (wt/vol) PEG6000, Fz4~CRD~ crystal form I in 1.6 M tri-sodium citrate, pH 6.5, and Fz4~CRD~ crystal form II in 0.1 M HEPES, pH 7.5, 0.1 M NaCl, 1.6 M ammonium sulfate. For the Norrin--Fz4~CRD~--SOS complex, protein complex was mixed with 10 mM SOS (Toronto Research Chemicals Inc.) prior to crystallization and crystals were obtained in 0.1 M Tris, pH 8.0, 0.15 M NaCl, 8% (wt/vol) PEG8000. For cryoprotection, crystals were soaked in mother liquor supplemented with 30% (vol/vol) glycerol for methylated Norrin--Fz4~CRD~, with 20% (vol/vol) PEG200 and 10 mM SOS for Norrin--Fz4~CRD~--SOS, with 30% (vol/vol) PEG550MME for Norrin crystal form II, with 30% (vol/vol) glycerol for Norrin crystal form III, with 1.8 M tri-sodium citrate, pH 6.5 for Fz4~CRD~ crystal form I, and with 23% (vol/vol) sucrose for Fz4~CRD~ crystal form II and subsequently flash-cooled by dipping into liquid nitrogen. The crystals of Norrin crystal form I were frozen directly. Data were collected at 100 K at Diamond Light Source (Oxfordshire, UK) at beamlines I03 (Norrin Se-Met), I04 (methylated Norrin--Fz4~CRD~ and Norrin crystal form II and III), I04-1 (Norrin--Fz4~CRD~--SOS), and I24 (Norrin crystal form I and Fz4~CRD~ crystal form I and II). Diffraction data were indexed and integrated using XIA2 ([@bib88]) coupled with XDS or IMOSFLM, and scaled and merged using Aimless ([@bib30]). A subset of 5% of randomly selected diffraction data were used for calculating *R*~free~ ([@bib16]).

Structure determination and refinement {#s4-5}
--------------------------------------

The structure of Norrin crystal form I was solved using highly redundant single-wavelength anomalous dispersion data merged from four data sets and collected at the Se K absorption edge. HKL2MAP ([@bib76]) was used to identify the Se sites, which were then fed into PHENIX AUTOSOL ([@bib2]), resulting in an interpretable density modified electron map generated by RESOLVE ([@bib80]). An initial model generated by BUCCANEER ([@bib25]) was used to solve the high-resolution native structures. The structure of Fz4~CRD~ was determined by molecular replacement (MR) in PHASER ([@bib49]) using mouse Fz8~CRD~ (PDB ID: 1IJY) as the search model, which was modified by CHAINSAW. For the determination of methylated Norrin--Fz4~CRD~, Norrin was used as search model for MR in PHASER ([@bib49]) to obtain the initial phases. The additional electron density corresponding to Fz4~CRD~ was clearly discernible after density modification with PARROT ([@bib26]). Subsequently, the complex structure was solved by searching for Fz4~CRD~ with MR in PHASER ([@bib49]). All other structures were solved by MR in PHASER ([@bib49]) using the refined Norrin and Fz4~CRD~ structures as search models. The models were completed by manual rebuilding in COOT ([@bib28]) and refinement in REFMAC5 ([@bib51]) and PHENIX ([@bib1]). The crystallographic statistics are listed in [Table 1](#tbl1){ref-type="table"}. All models were validated with MOLPROBITY ([@bib20]).

Structure analysis {#s4-6}
------------------

Amino acid sequence alignments were constructed using ClustalW ([@bib81]). Structure superposition was performed within the CCP4 program suite using the SSM algorithm ([@bib43]). Electrostatic potential calculations were generated using APBS tools ([@bib11]), surface sequence conservation was calculated using CONSURF ([@bib7]) and interface areas of proteins were analyzed with the PISA web server ([@bib44]). High-quality images of the molecular structures were created with the PyMOL Molecular Graphics System (Version 1.5, Schrödinger, LLC). Schematic figures and other illustrations were prepared using Corel Draw (Corel Corporation).

Surface plasmon resonance equilibrium binding studies {#s4-7}
-----------------------------------------------------

SPR experiments were performed using a Biacore T200 machine (GE Healthcare Life Sciences) at 25°C in 10 mM HEPES, pH 7.5, 0.15 M NaCl, 0.005% (wt/vol) Tween20. For in vivo biotinylation ([@bib59]), Norrin wild-type or mutants in the pHL-Avitag3 vector ([@bib6]) were co-transfected with a pHLsec construct of BirA-ER (the synthetic BirA gene with a C-terminal KDEL sequence for retention in the endoplasmic reticulum) in HEK293T cells. Mutant proteins were secreted at similar levels to the wild-type proteins. The mammalian cell secretory pathway uses stringent quality control mechanisms to ensure that secreted proteins are correctly folded ([@bib82]). The biotinylated Norrin variants were immobilized onto the surface of a CM5 sensor chip (GE Healthcare Life Sciences) on which approximately 8500 resonance units of streptavidin were coupled via primary amines. Fz4~CRD~ proteins used as analytes were expressed in HEK293T cells to ensure full glycosylation and prepared as described above. The signal from SPR flow cells was corrected by subtraction of a blank and reference signal from a mock-coupled flow cell. In all analyses, the experimental trace returned to baseline line after a regeneration step with 100 mM phosphate pH 3.7, 2 M NaCl, 1% (wt/vol) Tween20. The data were fitted to a 1:1 Langmuir adsorption model (*B* = *B*~max~*C*/(*K*~d~ + *C*), where *B* is the amount of bound analyte and *C* is the concentration of analyte in the sample) for the calculation of dissociation constant (*K*~d~) values using Biacore Evaluation software (GE Healthcare Life Sciences). Data points correspond to the average from two independent dilution series.

Small-angle x-ray scattering experiment {#s4-8}
---------------------------------------

Solution scattering data were collected at beamline BM29 of the European Synchrotron Radiation Facility (ESRF; Grenoble, France) at 293 K within a momentum transfer range of 0.01 Å^−1^ \< *q* \< 0.45 Å^−1^, where *q* = 4πsin(θ)/λ and 2θ is the scattering angle ([@bib61]). X-ray wavelength was 0.995 Å and data were collected on a Pilatus 1M detector. Fz4~CRD~ was measured at 1.47 and 3.10 mg/ml (deglycosylated form) and 0.97 and 1.45 mg/ml (glycosylated form) in 10 mM HEPES pH 7.5, 0.15 M NaCl. Norrin was measured at 0.75 and 1.26 mg/ml in 10 mM HEPES, pH 7.5, 0.7 M NaCl, 0.5% (wt/vol) CHAPS. The deglycosylated Norrin--Fz4~CRD~ complex was measured at 1.02 and 2.14 mg/ml in 10 mM HEPES, 0.5 M NaCl. Data reduction and calculation of invariants was carried out using standard protocols implemented in the ATSAS software suite ([@bib63]). A merged dataset was obtained by merging the low-angle part of the low-concentration dataset with the high-angle part of the high-concentration dataset. The Radius of gyration (*R*~g~) was obtained from Guinier plot using AutoRg ([@bib63]). The maximum dimension of the particle (*D*~max~) and Volume Porod (*V*~p~ \[nm^3^\]) were calculated by GNOM ([@bib79]). Molecular weights were obtained by (a) comparison with the reference bovine serum albumin (BSA) and (b) dividing the Porod Volume by 1.66 ([@bib64]). Theoretical X-ray scattering patterns of structural models were calculated and fitted to experimental X-ray scattering curves using the program FoXS ([@bib72]). The Norrin, Fz4~CRD~ and the Norrin--Fz4~CRD~ complex solution structures were modeled starting from their respective crystal structures. Complex glycan structures and missing regions of N- and C-termini were added using the program Modeller ([@bib29]). All-atom simulations, and calculation and fitting of scattering patterns of Norrin, Fz4~CRD~ and the Norrin--Fz4~CRD~ complex were performed using the automated AllosMod-FoXS procedure ([@bib33]).

Size-exclusion chromatography coupled to multi-angle light scattering analysis {#s4-9}
------------------------------------------------------------------------------

SEC-MALS experiments were performed by using SEC on an analytical Superdex S200 10/300 GL column (GE Healthcare Life Sciences) connected to online static light-scattering (DAWN HELEOS II, Wyatt Technology, Santa Barbara, CA), differential refractive index (Optilab rEX, Wyatt Technology, Santa Barbara, CA) and Agilent 1200 UV (Agilent Technologies, Santa Clara, CA) detectors. Purified sample (Fz~CRD~ proteins at 50 μM or Norrin--Fz4~CRD~ complex at 25 μM) was injected into a column equilibrated in 10 mM HEPES, pH 7.5, 0.15 mM NaCl. Molecular mass determination was performed using an adapted RI increment value (*dn*/*dc* standard value; 0.186 ml/g) to account for the glycosylation state. The theoretical molecular weight was predicated from amino acid sequence plus 2.35 kDa per N-linked glycosylation site for full glycosylated protein produced from HEK293T cells or 203 Da per site for deglycosylated protein produced from HEK293T cells in the presence of kifunensine ([@bib18]) with limited glycosylation and treated with Endo-F~1~. Data were analyzed using the ASTRA software package (Wyatt Technology, Santa Barbara, CA).

Luciferase reporter assay {#s4-10}
-------------------------

The stable HEK293STF cell lines ([@bib89]) carrying the Super Top Flash firefly luciferase reporter were split into 96-well plates and transfected 24 hr later with 200 ng DNA per well using Lipofectamine 2000 (Life Technologies, UK) according to the manufacturer\'s instructions. For assessment of interface mutants used in SPR experiments, the DNA mix contained 80 ng Norrin plasmid, 40 ng each of Fz4 and Lrp6 plasmids, 20 ng each of Tspan-12 and constitutive *Renilla* luciferase plasmids (pRL-TK, Promega, Madison, WI). The firefly and *Renilla* luciferase activities were measured 48 hr later with Dual-Glo luciferase reporter assay system (Promega, Madison, WI) using an Ascent Lunimoskan luminometer (Labsystems). For evaluation of recombinant Norrin and SOS inhibition, the DNA mix (80 ng pLEXm plasmid, 40 ng each of Fz4 and Lrp6 plasmids, 20 ng each of Tspan-12 and pRL-TK plasmids) was used for transfection. Cells were stimulated 6 hr post transfection with 9 μg/ml Norrin, 9 μg/ml Norrin preincubated with 2 mM SOS for 15 min, or control 9 μg/ml Fetal Calf Serum (FCS). The Dual-Glo luciferase reporter assays were performed 48 hr later. The firefly luciferase activity was normalized to *Renilla* luciferase activity (relative light unit, RLU). Luciferase reporter assays were performed 3 times in triplicate.

Heparin affinity chromatography {#s4-11}
-------------------------------

Protein samples produced in HEK293T cells were freshly purified by SEC and then adjusted in 50 mM Tris, pH 7.5, 0.25 M NaCl. Purified protein (0.5 mg) was loaded onto a 1 ml HiTrap heparin HP column (GE Healthcare Life Sciences) equilibrated in 20 mM Tris, pH 7.5, 0.25 M NaCl and eluted with a linear NaCl gradient to 20 mM Tris, pH 7.5, 2 M NaCl, 5% (wt/vol) glycerol over 10 column volumes. Notably, we found that Norrin--Fz4~CRD~ complex tends to partially disassemble (Fz4~CRD~ detected in flow-through; [Figure 7A](#fig7){ref-type="fig"}) during sample preparation for the heparin binding assay (NaCl concentration was reduced from 0.5M to 0.25M).
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Thank you for sending your work entitled "Structure and functional properties of Norrin mimic Wnt for signalling with Frizzled4, Lrp5/6, and proteoglycan" for consideration at *eLife*. Your article has been favorably evaluated by John Kuriyan (Senior editor) and two reviewers.

The Reviewing editor and the other reviewers discussed their comments before we reached this decision, and the editor has assembled the following comments to help you prepare a revised submission.

Chang et al. report structural and functional studies of Norrin, its binding partner Fz4~CRD~, and the Norrin:Fz4~CRD~ complex. They develop a mammalian expression system to produce functional Norrin, a member of a class of cystine-knot ligands that are often notoriously difficult to express. They crystallize and determine the structure of Norrin alone, of Fz4~CRD~ alone, and complexes of Norrin with Fz4~CRD~ and Fz4~CRD~ and sucrose-octasulfate (SOS), frequently used as a glycosaminoglycan (GAG) mimic. These structures, and the ensuing functional analysis, establish important features of Norrin biology. First, the authors show a 2:2 Norrin:Fz4~CRD~ binding stoichiometry, mediated by a large interface between each monomer within the Norrin dimer with a molecule of Fz4~CRD~ (located on opposite ends of the Norrin dimer). This interface is comprised of an extensive network of interacting residues on two beta-hairpins in Norrin with those on three loops in Fz4~CRD~. Second, the authors describe a putative glycosaminoglycan binding surface (surmised from the observed location of two SOS molecules in the crystal structure of the complex) composed of residues on both Norrin and Fz4~CRD~. Third, the authors point out a resemblance between the way in which Norrin interacts with Fz4~CRD~ and that in which Wnt8 interacts with Fz8~CRD~ (from a previous publication). Specifically, the position of the Wnt8 "index finger", which interacts with the so called "site 2" on Fz8~CRD~, overlaps with strands b1 and b2 of Norrin, which interact with the analogous region on Fz4~CRD~. Furthermore, these beta-strands in Norrin show some structural equivalence with Wnt8. Finally, based on an analysis of solvent exposure, disease association, and lack of involvement in Fz4~CRD~ or GAG binding, the authors propose a positively charged, concave patch on the surface of Norrin as the putative binding site for Lrp5/6.

The core new result here is the crystal structure of the complex of Norrin with Fz4~CRD~/SOS and studies attempting to distinguish sites of GAG and LRP5/6 binding. Although the precise implications of these results for the signaling mechanism remain to be fleshed out, these results will form the basis of future studies and form an essential component of emerging models of Norrin/Wnt signaling.

There is a previously published study on the structure of Norrin fused to MBP (Ke et al. Genes and Development 2013), which closely resembles the structures of Norrin presented here (as the authors demonstrate in [Figure 2-figure supplement 3C and 3D](#fig2s3){ref-type="fig"}, and [Figure 4-figure supplement 4](#fig4s4){ref-type="fig"}). Despite some overlap between the current manuscript and the previously published study, the paper under consideration represents an important contribution to the structural and biochemical analysis of a receptor-ligand interaction that plays an important role in both normal physiology and disease (and that is of considerable therapeutic interest given its potential involvement in vascular diseases of the retina).

The manuscript could be improved and shortened by more judicious citation of the literature and by clearing up---or acknowledging---weakness in the experiments and arguments, as indicated in the comments below.

Major issues to be addressed:

1\) A principal scientific concern is the conclusion that the R121W site represents the LRP5/6 binding site. This conclusion may be correct, it just isn\'t fully supported by the data. Indeed, there is no direct measurement of the Norrin-Lrp5/6 interaction in the paper. Loss of signaling from the R121W mutation could also stem from loss of GAG interactions; this site is highly positively charged. The principal rationale for this site being the LRP5/6 interaction site seems to be that it is distinct from the better characterized (by the authors) GAG-binding site (SOS binds there and mutations knockout heparin binding), but it cannot be ruled out that the second site is also a GAG binding site. If the authors wish to make a claim for identification of an LRP binding site they should at least show that the R121W still binds a heparin column as tightly as wild type, or, better yet, show that R121W Norrin doesn\'t bind LRP-or tone down or qualify the section (already a bit qualified) on identification of the LRP binding site.

It is important that the authors address this issue, especially since it is one of the main points of discrepancy with Ke et al. (as the authors point out "Verification of GAG binding site"). The authors suggest that the site proposed by Ke el. al. to be the Lrp5/6 binding site on Norrin is in fact the SOS/GAG binding site and that their analysis has revealed the true Lrp5/6 binding site (notably, Ke et. al. did measure binding between Norrin and Lrp6).

2\) [@bib42] report the expression, crystallization, and X-ray structure determination of an MBP-Norrin fusion protein that is refolded after expression in *E. coli*. Therefore, claims of "technical difficulties generating recombinant Norrin", in the present manuscript (Introduction), are overstated, if not misleading. The prior work was published more than a year ago, and the time has passed for the authors to present their work as competing with Ke, as opposed to building on Ke. The descriptions of the Norrin structure in the text and [Figure 2](#fig2){ref-type="fig"} appear to be unnecessarily redundant with the earlier work, and the MS would benefit by focusing on comparisons of their structures with the earlier structure to highlight flexible/conserved regions, e.g. as shown in [Figure 2-supplement 3 D and E](#fig2s3){ref-type="fig"}.

3\) The statement "...there have been no quantitative determinations of the binding affinity of Norrin for different CRD of Fz" (Results) is also misleading because both [@bib42] and [@bib89] report single-digit nanomolar affinities of Norrin for Fc-dimerized Fz4~CRD~. The affinity of the interaction between Norrin and Fz4~CRD~ is significantly different between this study (∼1 micromolar by SPR) and the prior study of Ke et. al. (∼10 nM by Alphascreen and the Octet Red instrument). These studies may be a bit different in that they use a dimerized CRD, which is presumably why the earlier authors measured tighter binding owing to avidity, but these measurements are certainly quantitative and even perhaps more physiologically relevant given the apparent Fz4 dimerization on cells. This should be noted and potential explanations for this discrepancy should be discussed.

4\) The authors show that Norrin mutants in the SOS binding residues, especially the R107E/R109E/R115L mutant, show decreased activity in a luciferase assay for Wnt signaling ([Figure 6G](#fig6){ref-type="fig"}) and fail to bind to heparin (Figure 6-figure supplement 2B). Can the authors provide any evidence that Glycosaminoglycans (GAGs) play a positive role in cellular responses to Norrin as the authors suggest and draw in all their models? The physiological relevance of this interaction for signaling is important to establish since it is a central aspect of the structure.

5\) The authors propose that the SOS molecule in the structure (and presumably GAGs in cells; see model in Figure 6-figure supplement 2) bridges the interaction between Norrin and the Fz4~CRD~. As support, they reference a paper (Smallwood JBC 2007) that demonstrated heparin can enhance the affinity between Norrin and the Fz4~CRD~ by ∼10-fold. There is no direct experimental test of this model (except for a difficult-to-interpret experiment that excess SOS can decrease the signaling efficacy of Norrin). An easy (but important) test of this model would be to ask if (1) SOS or heparin can enhance the affinity of the Norrin-Fz4~CRD~ interaction in their SPR assay and (2) whether mutations in the putative SOS binding site of Norrin (e.g. the R107E/R109E/R115L triple mutation shown in Figure 6-figure supplement 2) can abrogate this effect of heparin/SOS (though they have little effect on the baseline Norrin-Fz4~CRD~ interaction).

6\) The authors state that owing to the fact that FzCRDs are monomeric at high concentration in solution "CRDs of Fz receptors... are not involved in receptor dimerization." Weak interactions in solution may yet be meaningful in 2D membranes and even if they don\'t contribute significantly energetically the observed contacts may form in Fz dimers (and influence the nature of the interaction) that form mostly based on favorable interactions of the TM regions.

7\) It is curious that a single Fz4~CRD~ bound to the Norrin dimer in the absence of SOS. Do the authors have any rationalization for this unexpected stoichiometry (crystallization conditions, etc.)?
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Author response

*Major issues to be addressed*:

*1) A principal scientific concern is the conclusion that the R121W site represents the LRP5/6 binding site. This conclusion may be correct, it just isn\'t fully supported by the data. Indeed, there is no direct measurement of the Norrin-Lrp5/6 interaction in the paper. Loss of signaling from the R121W mutation could also stem from loss of GAG interactions; this site is highly positively charged. The principal rationale for this site being the LRP5/6 interaction site seems to be that it is distinct from the better characterized (by the authors) GAG-binding site (SOS binds there and mutations knockout heparin binding), but it cannot be ruled out that the second site is also a GAG binding site. If the authors wish to make a claim for identification of an LRP binding site they should at least show that the R121W still binds a heparin column as tightly as wild type, or, better yet, show that R121W Norrin doesn\'t bind LRP-or tone down or qualify the section (already a bit qualified) on identification of the LRP binding site*.

It is important that the authors address this issue, especially since it is one of the main points of discrepancy with Ke et al. (as the authors point out "Verification of GAG binding site"). The authors suggest that the site proposed by Ke el. al. to be the Lrp5/6 binding site on Norrin is in fact the SOS/GAG binding site and that their analysis has revealed the true Lrp5/6 binding site (notably, Ke et. al. did measure binding between Norrin and Lrp6).

We thank the reviewers for urging us to give additional thought to these important issues. In response to their suggestions we have carried out a substantial amount of experimental work, the results of which we have added to the manuscript. We have also revised the text to clarify and discuss in detail points of agreement and discrepancy between our work and interpretation of results, and that of Ke et al. ([@bib42]). We have paid particular attention, at all points in the manuscript, to check that our interpretations of the currently available data are clearly qualified when appropriate.

Firstly, we have carried out SPR binding experiments for the interaction of wild-type Norrin with Lrp6, and we have added these data to the manuscript ([Figure 7E](#fig7){ref-type="fig"}). In our assay we measured an affinity of 2.87 μM for Norrin binding to Lrp6; Ke et al. reported a *K*~d~ value of 0.45 μM based on a homologous AlphaScreen competition assay using MBP-Norrin and Lrp6 ([@bib42]). We note this difference in affinity values (presumably resulting from the very different assay formats) in the discussion.

Secondly, as suggested by the reviewers, we performed heparin binding assays. These experiments show Norrin R121W mutant still binds to heparin with a high affinity ([Figure 8--figure supplement 1C](#fig8s1){ref-type="fig"}) similar to Norrin wild-type ([Figure 7--figure supplement 1A](#fig7s1){ref-type="fig"}). However, as a result of performing the additional protein production and functional assays for the Norrin R121W mutant we discovered that this protein has lower solubility and stability than wild-type. We have added this information to the section on "Mapping a potential Lrp5/6 binding site on Norrin" and to the figure legend of [Figure 8--figure supplement 1C](#fig8s1){ref-type="fig"}. This protein behaviour proved very problematic when we attempted to carry out SPR measurements of Norrin R121W mutant binding to Lrp6. We have therefore been unable to include this experiment in our revision.

Thirdly, we have toned down and qualified statements in the section "Mapping a potential Lrp5/6 binding site on Norrin". We believe that the revised manuscript provides readers with a balanced assessment of the available data for the Norrin and Lrp5/6 interaction drawn from our current studies and those previously reported by Ke et al. Specifically, Ke et al. proposed the Lrp5/6 binding site comprises positively charged residues (Lys54, Arg107, Arg109, Arg115) and hydrophobic residues (Leu52 and Tyr53). They generated MBP-Norrin K54E/R109E mutant and found the double mutations impair Lrp6 binding in a competition assay (MBP-Norrin against the interaction of Lrp6~P1E1P2E2~ and DKK1 peptide). Actually, these results are in partial agreement with our proposed Lrp5/6 binding site, because our current studies also suggest that the Lys54 residue is involved in Lrp5/6 binding ([Figure 8](#fig8){ref-type="fig"}). However, our structural ([Figure 5E](#fig5){ref-type="fig"}) and functional assays ([Figure 7](#fig7){ref-type="fig"} and [Figure 7--figure supplement 1](#fig7s1){ref-type="fig"}) suggest that Arg109, the second residue of the MBP-Norrin K54E/R109E mutant, contributes to GAG binding rather than Lrp5/6 binding. We now clarify these points in the revised manuscript, placing our results in context with the previous studies with clear discussions in the sections on "Verification of GAG binding site" and "Mapping a potential Lrp5/6 binding site on Norrin".

*2)* [@bib42] *report the expression, crystallization, and X-ray structure determination of an MBP-Norrin fusion protein that is refolded after expression in* E. coli*. Therefore, claims of* "*technical difficulties generating recombinant Norrin*"*, in the present manuscript (Introduction), are overstated, if not misleading. The prior work was published more than a year ago, and the time has passed for the authors to present their work as competing with Ke, as opposed to building on Ke.. The descriptions of the Norrin structure in the text and* [*Figure 2*](#fig2){ref-type="fig"} *appear to be unnecessarily redundant with the earlier work, and the MS would benefit by focusing on comparisons of their structures with the earlier structure to highlight flexible/conserved regions, e.g. as shown in* [*Figure 2-supplement 3 D and E*](#fig2s3){ref-type="fig"}*.*

We thank the reviewers for these suggestions. In response we have revised our text for Norrin protein production (Introduction section). We also have condensed our description of the Norrin structure ("Production of biologically active Norrin"), and rearranged [Figure 2](#fig2){ref-type="fig"} and [Figure 2--figure supplement 3](#fig2s3){ref-type="fig"} to address the reviewers' comments and fully exploit the availability of the structure from the prior studies of [@bib42]. However, we think our current shortened description of the Norrin apo structure is necessary to orient readers before the results sections on the complex and binding studies.

*3) The statement* "*...there have been no quantitative determinations of the binding affinity of Norrin for different CRD of Fz*" *(Results) is also misleading because both* [@bib42] *and* [@bib89] *report single-digit nanomolar affinities of Norrin for Fc-dimerized Fz4*~*CRD*~*. The affinity of the interaction between Norrin and Fz4*~*CRD*~ *is significantly different between this study (∼1 micromolar by SPR) and the prior study of Ke et. al. (∼10 nM by Alphascreen and the Octet Red instrument). These studies may be a bit different in that they use a dimerized CRD, which is presumably why the earlier authors measured tighter binding owing to avidity, but these measurements are certainly quantitative and even perhaps more physiologically relevant given the apparent Fz4 dimerization on cells. This should be noted and potential explanations for this discrepancy should be discussed*.

We appreciate the reviewers' comments and have taken all of them into account in the revised manuscript. Specifically:

Ke et al., and Xu et al, indeed did quantitative measurements of Norrin binding to Fc-dimerized Fz4~CRD~ ([@bib89], [@bib42]), but they did not detect significant interactions, and therefore measure the binding affinity, of Norrin with the CRDs of other Frizzled receptors. From our structural comparison of Fz4~CRD~ with Fz8~CRD~ ([Figure 9D-F](#fig9){ref-type="fig"}), we hypothesised that Fz8~CRD~ could have some ability to interact with Norrin. We therefore pursued studies to measure binding affinity values between Norrin and the CRDs of Frizzled receptors including Fz5~CRD~, Fz7~CRD~, and Fz8~CRD~. We agree with reviewers' comment that our original wording is misleading and have changed the sentence "Because there have been no quantitative determinations of the binding affinity of Norrin for different CRD of Fz" to "To determine the binding affinity of Norrin for different CRD of Fz".

Regarding the differences in affinity values from prior studies ([@bib89], [@bib42]), we originally briefly explained this issue in the figure legend of [Figure 6--figure supplement 1](#fig6s1){ref-type="fig"}. However, the reviewers made some excellent comments, which we have exploited in our revised text; we have moved our previous explanation from the figure legend of [Figure 6--figure supplement 1](#fig6s1){ref-type="fig"} to the Discussion section and now discuss in more detail.

*4) The authors show that Norrin mutants in the SOS binding residues, especially the R107E/R109E/R115L mutant, show decreased activity in a luciferase assay for Wnt signaling (*[*Figure 6G*](#fig6){ref-type="fig"}*) and fail to bind to heparin (Figure 6-figure supplement 2B). Can the authors provide any evidence that Glycosaminoglycans (GAGs) play a positive role in cellular responses to Norrin as the authors suggest and draw in all their models? The physiological relevance of this interaction for signaling is important to establish since it is a central aspect of the structure*.

We thank the reviewers for raising this point. We have indeed considered taking forward studies to explore the role of HSPGs in Norrin signalling. We agree with the reviewers that this is an interesting and important question to address, however, we consider that to do so fully will require substantial work that is beyond the scope of our current study. Therefore, in response to this comment:

Firstly, we have included new data from the SPR binding assay ([Figure 7F](#fig7){ref-type="fig"}) to show the Norrin mutant (R107E/R109E/R115L) in the GAG binding site retains the ability to bind to Lrp6~P1E1P2E2~. We have made a new [Figure7](#fig7){ref-type="fig"}, which is focused on the verification of the GAG binding site, and have added additional description of our results to the section on "Verification of GAG binding site".

Secondly, we have added more description and clarified our discussion of HSPGs in the Discussion section.

Thirdly, we have taken note of the reviewers' concerns (in comments 4 and 5) and on reflection have come to the conclusion that our schematics in various figures may give the reader a too simplistic impression of the possible ways in which GAGs may contribute to Norrin signalling. We have therefore decided to remove the old [Figure 8G](#fig8){ref-type="fig"} (cartoon model of Norrin induced receptor clustering and signallosome formation) and figure 6-figure supplement 2D.

*5) The authors propose that the SOS molecule in the structure (and presumably GAGs in cells; see model in Figure 6-figure supplement 2) bridges the interaction between Norrin and the Fz4*~*CRD*~*. As support, they reference a paper (Smallwood JBC 2007) that demonstrated heparin can enhance the affinity between Norrin and the Fz4*~*CRD*~ *by ∼10-fold. There is no direct experimental test of this model (except for a difficult-to-interpret experiment that excess SOS can decrease the signaling efficacy of Norrin). An easy (but important) test of this model would be to ask if (1) SOS or heparin can enhance the affinity of the Norrin-Fz4*~*CRD*~*interaction in their SPR assay and (2) whether mutations in the putative SOS binding site of Norrin (e.g. the R107E/R109E/R115L triple mutation shown in Figure 6-figure supplement 2) can abrogate this effect of heparin/SOS (though they have little effect on the baseline Norrin-Fz4*~*CRD*~ *interaction)*.

We appreciate the reviewers' comments regarding the speculative nature of our model for the role of SOS/GAG molecule as an additional component of the Norrin--Fz4~CRD~ complex. We have undertaken a series of additional experiments and whilst we are able to provide substantial extra data in support of the distinct nature of the GAG binding site on Norrin we cannot provide definitive evidence for the particular importance of a bridging role in complex formation. We have accordingly re-balanced our discussion of this point throughout the revised manuscript. Specifically:

We apologize for not being clearer in our description of how excess SOS can inhibit Norrin signalling and have clarified our discussion of this experiment in the Discussion section by referencing two examples in which exogenous heparin and PG545 (a heparan sulphate mimetic) have been shown to inhibit Wnt signalling by competition with endogenous HSPGs for ligand and/or receptor interactions ([@bib4], [@bib36]). In an attempt to respond fully to the reviewers' comments we have tried to measure the binding affinity of Norrin wild-type or R107E/R109E/R115L mutant with Fz4~CRD~ in the presence of SOS. However, we could not detect consistent, significant, changes in affinity using our SPR assay. On reflection we suspect that because the GAG binding site spans Norrin and Fz4~CRD~ ([Figure 5E](#fig5){ref-type="fig"}), the inhibitory effects of separate Norrin-SOS binding and Fz4~CRD~--SOS binding events blocking formation of Norrin-SOS- Fz4~CRD~ (similar to in our SOS inhibition assay; [Figure 7--figure supplement 1D](#fig7s1){ref-type="fig"}) may cancel out any stabilizing contribution to complex formation in these in vitro measurements.

It remains noteworthy that crystals of the native Norrin--Fz4~CRD~ complex only grew in the presence of SOS ([Figure 4A](#fig4){ref-type="fig"}) and that the structural analysis reveals a SOS molecule spanning the interface between Norrin and Fz4~CRD~ ([Figure 4E](#fig4){ref-type="fig"}). This 'bridging' action does suggest a mechanism by which to explain the observation of Smallwood et al. of an approximate 10-fold enhancement for the affinity between Norrin and Fz4~CRD~ in the presence of heparin. We therefore feel it is reasonable to retain some mention of the possible relevance of the 'SOS bridge' for promoting signalling complex formation in the revised manuscript.

In our original manuscript we reported that mutations (R107E/R109E/R115L) in the Norrin GAG binding site do not affect the ability of Norrin to bind Fz4~CRD~ ([Figure 7D](#fig7){ref-type="fig"}) but do impair the activation of signalling ([Figure 7C](#fig7){ref-type="fig"}). We have now carried out additional experiments to demonstrate Norrin R107E/R109E/R115L--Fz4~CRD~ complex formation ([Figure 7--figure supplement 1B](#fig7s1){ref-type="fig"}), and interaction with Lrp6~P1E1P2E2~ ([Figure7F](#fig7){ref-type="fig"}) and have also confirmed that these mutations impair heparin binding ([Figure 7B](#fig7){ref-type="fig"}). In combination, these data suggest that the GAG binding site is independent from the Fz4 and putative Lrp5/6 binding sites.

*6) The authors state that owing to the fact that FzCRDs are monomeric at high concentration in solution* "*CRDs of Fz receptors... are not involved in receptor dimerization.*" *Weak interactions in solution may yet be meaningful in 2D membranes and even if they don\'t contribute significantly energetically the observed contacts may form in Fz dimers (and influence the nature of the interaction) that form mostly based on favorable interactions of the TM regions*.

We agree with the reviewers. We cannot exclude the possibility that the CRDs of Fz receptors contribute to receptor dimerization in the cell membrane even though our *in vitro* solution studies indicate their interactions are very weak. We now state this when discussing these results.

*7) It is curious that a single Fz4*~*CRD*~ *bound to the Norrin dimer in the absence of SOS. Do the authors have any rationalization for this unexpected stoichiometry (crystallization conditions, etc*.*)?*

We think this is a very interesting question. Certainly such results are not unique, for example the case of colony stimulating factor-1 (CSF-1) and CSF-1 receptor, in which dimeric CSF-1 is bound to one molecule of CSF-1R in the crystal structure (Chen et al., 2008)

We had actually investigated what might be reason for our 2:1 complex structure, but decided to omit our findings from the original manuscript because we felt they might not be of sufficiently general interest. In our methylated Norrin--Fz4~CRD~ complex ([Figure 4--figure supplement 1B](#fig4s1){ref-type="fig"}), we found that two lysine residues involved in the Norrin--Fz4~CRD~ interface are dimethylated in the uncomplexed subunit of the Norrin dimer. We have included this structural analysis in [Figure 4--figure supplement 1C](#fig4s1){ref-type="fig"} and added some comments to the section "The crystal structure of Norrin in complex with Fz4~CRD~".

[^1]: Department of Biochemistry, University of Oxford, Oxford, United Kingdom.

[^2]: Evotec Ltd., Oxford, United Kingdom.

[^3]: All structures were determined from one crystal.

[^4]: Values in parentheses are for highest-resolution shell.

[^5]: *R*~g~ is Radius of gyration, calculated from Guinier plot using AutoRg ([@bib63]).

[^6]: *D*~max~ is the maximum dimension of the particle, calculated by GNOM ([@bib79]).

[^7]: The theoretical molecular weight (MW~Theoretical~) is predicated from amino acid sequence plus the molecular weight of N-linked glycans (see 'Materials and methods', ***SEC-MELS analysis*** for detailed information of calculation).

[^8]: The measured molecular weight (MW~Measured~) is calculated from forward scattering of sample (*I*(0)) by comparison with reference bovine serum albumin (BSA).

[^9]: The measured molecular weight (MW~Measured~) is obtained by dividing the Volume Porod (*V*~p~ \[nm^3^\]) by 1.66 ([@bib64]).

[^10]: The proteins were produced from HEK293T cells in the presence of kifunensine with limited glycosylation and treated with endoglycosidase-F~1~.

[^11]: The proteins were produced from HEK293T cells with full glycosylation.

[^12]: The proteins were produced from HEK293T cells in the presence of the N-glycosylation processing inhibitors, kifunensine resulting in limited glycosylation and were treated with endoglycosidase-F~1~.

[^13]: The proteins were produced from HEK293T cells with full glycosylation.

[^14]: The measured molecular weight (MW~Measured~) is in general agreement with theoretical molecular weight (MW~Theoretical~) predicated based on the primary sequence plus the molecular weight of N-linked glycans (see 'Materials and methods', ***SEC-MELS analysis*** for detailed information of calculation).
